The AtlasProteins
Adiponectin
The hormone fat makes less of the more fat there is: found four times in a single year, celebrated for more than a decade as the body's own insulin sensitizer, and then shown by human genetics to be, for diabetes and heart disease, mostly a reading of metabolic health rather than its cause.
- Gene
- ADIPOQ on chromosome 3q27, about 17 kilobases, three exons and two introns 4
- Protein
- 244 amino acids in humans, 247 in mouse: signal sequence, short non-helical region, 22 Gly-X-Y collagen repeats and a globular C1q-like head 2,5
- Structure
- Globular head crystallized as a trimer at 2.1 angstroms, folded like tumor necrosis factor 6
- Circulating forms
- Trimer, hexamer (low molecular weight) and high-molecular-weight multimers; the larger forms need a disulfide bond near the start of the chain 7,8
- Receptors
- AdipoR1 (muscle) and AdipoR2 (liver), seven-pass membrane proteins in the reverse orientation of G-protein-coupled receptors, with low intrinsic ceramidase activity; T-cadherin binds hexamers and HMW forms 9,10,11,12
- First described
- Four times in 1995-1996 as Acrp30, apM1, AdipoQ and GBP28; named adiponectin in 1999 1,2,3,5,13
- Typical level
- Micrograms per milliliter; in 182 Seattle adults, women averaged 7.4 and men 5.4 14
- Low in
- Obesity, insulin resistance, type 2 diabetes, steatohepatitis and generalized lipodystrophy 3,15,16,17,18
- High in
- Women, older and leaner people, after weight loss, with thiazolidinediones, incretin drugs, SGLT2 inhibitors and rimonabant; in chronic heart failure it rises with NT-proBNP, and natriuretic peptides raise it 14,19,20,21,22,23,24,25
In brief
What it is
Adiponectin is a protein made almost entirely by fat cells and released into the blood in unusually large amounts, measured in micrograms (millionths of a gram) per milliliter 1,36,37. Its gene, ADIPOQ, spans about 17,000 letters of DNA at band 3q27 on chromosome 3 and is built of three exons, the stretches that code for protein 4. The human chain of 244 amino acids carries a signal sequence that marks it for export from the cell, a stalk of 22 collagen-like repeats and a globular head related to C1q, a protein of the immune system; the head's crystal structure turned out to share the fold of tumor necrosis factor, an inflammatory signaling protein 5,6. The chains wind together in threes, and the threes assemble into hexamers of six chains and larger high-molecular-weight complexes, so what circulates is a mixture of shapes 7,8.
Why it matters
Blood levels fall as fat accumulates and are low in obesity, in insulin resistance (when muscle, liver and fat respond weakly to insulin), in type 2 diabetes and in fatty liver with inflammation 3,15,17. In 13 studies that measured adiponectin and then followed 14,598 people forward, each one-unit step up on a logarithmic scale, a fixed multiple of the level rather than a fixed amount, went with a 28 percent lower risk of type 2 diabetes 38. In mice, giving the protein reversed insulin resistance and deleting it worsened insulin resistance on a high-fat diet, which led the Tokyo group to propose replenishing adiponectin as a treatment for insulin resistance and type 2 diabetes 39,40,41. Then two findings broke the simple story: high levels predict earlier death in heart failure, in older men and in some kidney-disease cohorts 24,42,43,44; and Mendelian randomization studies, which use inherited gene variants as a natural experiment, found in tens of thousands of people no consistent evidence that genetically lower adiponectin causes type 2 diabetes or coronary heart disease 26,28.
When it is lost
The deepest losses are in generalized lipodystrophy, where fat itself is missing: in 18 people with the congenital form the median was 1.5 micrograms per milliliter, against 6.9 in 46 people with the partial Dunnigan type, an inherited form in which fat is lost from the limbs and trunk 18. Rare ADIPOQ mutations that stop the chains assembling, such as R112C and I164T, each a swap of one amino acid at the numbered position, leave carriers with very low levels 4,7. In ordinary life the fall is gradual: men with type 2 diabetes and no coronary disease averaged 6.6 micrograms per milliliter against 7.9 in matched men without diabetes, and in 30,045 Copenhagen adults the lowest quarter, median 9.2, developed diabetes about four times as fast as the highest quarter, median 28.9, after adjustment (hazard ratio 4.05) 16,37. Whether the low level itself does the harm is a separate question, and the genetics mostly say it does not 26,27.
When it is stuck on
Levels run higher in women, in older and leaner people, and after weight loss, and drugs push them higher still: troglitazone, a thiazolidinedione diabetes drug since withdrawn for liver injury, roughly doubled them from 12.2 to 25.7 micrograms per milliliter even in lean volunteers in a study without a placebo group, and in a post hoc analysis written partly by its manufacturer's staff, tirzepatide, a weekly injected diabetes and weight-loss drug, raised them by 21 to 48 percent more than placebo over 72 weeks, depending on dose 14,19,20,21,45. The surprise is at the top in illness: among 195 people with chronic heart failure, those in the upper two thirds of adiponectin died at 3.23 times the rate of those in the lowest third after adjustment for NT-proBNP, a blood marker of heart strain; similar positive associations appear in older men and in some chronic kidney disease cohorts, though a 2025 meta-analysis of 12 kidney-disease studies found no overall association 24,42,43,44. This adiponectin paradox has several proposed explanations, and none rests on robust data 46.
On the current evidence adiponectin behaves less like a shield the body raises than like a gauge: a low reading marks insulin resistance and predicts diabetes, a high reading in a failing heart tracks strain and wasting, and the genetic studies have not shown that the level itself changes the risk of diabetes 24,26,46.
What adiponectin is: a collagen stalk, a globular head, and a great deal of it
Adiponectin is a hormone, a messenger carried in the blood, made almost entirely by fat cells, which biologists call adipocytes; proteins that fat cells secrete are called adipokines 1,2. When the first group described it in 1995, they noted that its messenger RNA, the working copy of a gene that a cell uses to build the protein, rose more than 100-fold as mouse precursor cells matured into fat cells in a dish, and that the protein was abundant in serum 1. Abundance is one of its peculiarities: a 2026 review counts unusually high levels among its defining features, alongside paradoxical associations with obesity and mortality and analytical difficulties 36. It is measured in micrograms, millionths of a gram, per milliliter of blood, and in a Danish population study of 30,045 adults the medians of the lowest and highest quarters were 9.2 and 28.9 micrograms per milliliter 37.
The gene, ADIPOQ, sits on the long arm of chromosome 3 at band 3q27 and spans about 17 kilobases, 17,000 letters of DNA, arranged as three exons, the stretches that code for protein, separated by two introns 4. That address mattered early. In 2000 a genome scan of 2,209 people in 507 families of European descent found a stretch of 3q27 linked to six traits of the metabolic syndrome, the cluster of glucose intolerance, abnormal blood fats and high blood pressure that travels with abdominal fat 47, and the next year the Tokyo group that would lead the field pointed out that the adiponectin gene lies in that region 39. Linkage of this kind narrows a search to a neighborhood; it does not prove that the gene in the neighborhood is responsible 47. Family studies put the share of the variation in blood levels explained by inheritance anywhere from 30 to 93 percent, depending on design, age, sex and ancestry 36.
The human protein is a chain of 244 amino acids 5. Reading from its starting end, it has a signal sequence that marks it for export from the cell, a short region with no regular structure, a stalk of 22 collagen repeats, in which every third amino acid is glycine, the Gly-X-Y pattern of collagen, the protein of tendon and skin, and finally a globular head 2,5. The mouse version has 247 amino acids, and its globular head resembles complement factor C1q, a protein of the immune system, as well as type X collagen and a brain protein called cerebellin 2. In 1998 the head was crystallized as a three-chain unit at 2.1 angstroms resolution, and its fold proved to be the same as that of tumor necrosis factor, an inflammatory signaling protein, which the authors read as evidence that the two families share an ancestor 6.
Because collagen stalks wind around one another, the chains travel in threes, and the threes assemble further. Serum from people and mice contains a range of sizes, from trimers through hexamers to complexes of high molecular weight, and the same range forms when the protein is made in cultured cells 7. The first group to purify the protein from human blood found that it behaved as a molecule of about 420 kilodaltons on one kind of separation but as single chains of 28 kilodaltons once its bonds were broken, a measure of how large the assemblies are 5.
In three sentences each
Made by fat, turned down by unhealthy fat
Fat cells switch the gene on as they mature, raising its messenger RNA more than 100-fold in culture, yet the more fat a person carries the less adiponectin circulates 1,3. Tumor necrosis factor alpha, an inflammatory signal made in excess in insulin-resistant states, suppresses the gene's promoter in fat cells, and in Pima Indians low levels tracked insulin resistance and fasting insulin more closely than the amount of fat 15,48. Fat inside the abdomen, together with age and sex, determined the level in a study of 182 adults whose abdominal fat was measured by computed tomography (CT) scanning 14.
One chain, three shapes
A disulfide bond, a sulfur-to-sulfur link through a cysteine amino acid near the start of the chain, is needed to build anything larger than a trimer of three chains, and human mutations that block assembly go with low levels and diabetes 7. The hexamer and high-molecular-weight forms, but not the trimer, bind T-cadherin, a binding protein on the cell surface 12. The high-molecular-weight form was argued from mouse and treatment studies to be the active hormone, although the same laboratory had earlier found chemically reduced trimers more potent at lowering glucose 8,49.
Receptors that are partly enzymes
AdipoR1, mostly in muscle, and AdipoR2, mostly in liver, cross the cell membrane seven times, like the G-protein-coupled receptors, a large family of hormone receptors, but they sit in the reverse orientation and are not members of that family 9,10. Their crystal structures show a zinc ion held by three histidine amino acids in a large internal cavity, and both receptors can split ceramide, a lipid that in excess promotes cell death, though the measured activity is low 11,50,51.
A fuel-sensing enzyme and fat burning, in mice
In mouse muscle and liver adiponectin activates AMP-activated protein kinase (AMPK), the enzyme cells use to sense a fuel shortage, increasing fatty-acid burning and in liver reducing glucose production; blocking AMPK blocked those effects 52. In people the evidence is correlational: in a cross-sectional study of 144 adults, which measured each person once, higher adiponectin went with greater insulin sensitivity measured by the glucose clamp, the reference test of insulin action (correlation coefficient r = 0.59, where 1 would be a perfect match) 15.
The words, defined
- Adipocyte
- A fat cell: a cell specialized to store fat as triglyceride and to release it when the body needs fuel.
- Adipokine
- Any signaling protein secreted by fat tissue; adiponectin and leptin are the best known.
- Exon and intron
- Exons are the stretches of a gene that end up coding for protein; introns are the stretches between them that are cut out of the messenger RNA.
- Collagen repeat (Gly-X-Y)
- A repeating three-amino-acid unit with glycine in every third position, which lets protein chains twist together into a rope-like triple helix.
- C1q
- A protein of the complement system, part of innate immunity; adiponectin's head domain resembles it.
- Microgram per milliliter
- A millionth of a gram in each milliliter of blood; adiponectin is typically present at several of these.
- Angstrom
- A ten-billionth of a meter; crystal structures at 2 to 3 angstroms resolve individual amino acids.
- Insulin resistance
- A state in which muscle, liver and fat respond less than normal to insulin, so the pancreas must make more insulin to keep blood sugar normal; insulin sensitivity is the same property measured the other way round.
- Kilodalton
- A unit of molecular mass; a protein of 30 kilodaltons weighs about 30,000 times as much as a hydrogen atom.
Found four times in a year, under four names
Adiponectin was described by four laboratories on two continents within eleven months, and each gave it a different name. In November 1995 Philipp Scherer, Harvey Lodish and colleagues at the Whitehead Institute in Cambridge, Massachusetts, reported Acrp30, adipocyte complement-related protein of 30 kilodaltons, made exclusively in fat cells and, like the fat-cell protein adipsin, secreted more when insulin was present 1. In April 1996 a group at Osaka University reported apM1, for adipose most abundant gene transcript 1, the commonest messenger RNA in human fat 13. In May 1996 Bruce Spiegelman's laboratory at the Dana-Farber Cancer Institute in Boston, using differential display, a technique that picks out genes active in one cell type and not another, reported AdipoQ and added the observation that would define the field: its messenger RNA was significantly reduced in the fat of obese mice and obese people 2. In October 1996 a group at Showa University in Tokyo, purifying proteins from human plasma that stick to gelatin, isolated GBP28, gelatin-binding protein of 28 kilodaltons, and recognized from its sequence that it was the protein encoded by apM1 5.
The name that stuck came three years later. In 1999 the Osaka group, having raised antibodies and built an enzyme-linked immunosorbent assay, ELISA, a test in which antibodies fixed to a plate capture the protein and a color reaction measures it, named the apM1 product adiponectin and reported what they called a paradoxical decrease: although fat is its source, obese people had significantly lower blood concentrations than people who were not obese 3. The abstract gives the healthy range as 1.9 to 17.0 milligrams per milliliter, a unit a thousand times larger than the micrograms per milliliter used in the group's subsequent reports, including its study of type 2 diabetes the following year 3,16.
Acrp30 survived for a few years in American papers. In 2001 scientists led by Lodish and a first author at Genset Corporation, a commercial genomics company in La Jolla, reported that a fragment containing only the globular head, cut free with a protein-splitting enzyme and called gAcrp30, lowered blood free fatty acids after a fatty meal, increased fat burning in muscle and produced sustained weight loss in mice on a high-fat, high-sugar diet without reducing food intake 54. The paper presented the fragment as a novel pharmacological compound, and the affiliation is a commercial interest a reader should keep in mind; the result was in mice only 54. Scherer's own later reviews use the name adiponectin 55.
The original papers could only speculate about function: two said outright that it was unknown or unclear 2,5, and the first suggested it might take part in the balance of food intake and fuel use 1. The idea that adiponectin is an insulin-sensitizing hormone arrived only in 2001, from mouse experiments described below 39,40.
Nov 1995Seen
Acrp30 at the Whitehead Institute
Scherer and Lodish describe a 30-kilodalton protein made only in fat cells and resembling complement C1q 1.Apr 1996Seen
apM1 in Osaka
The most abundant transcript in human fat is cloned and named apM1 13.May 1996Seen
AdipoQ, and the first sign it falls in obesity
Spiegelman's laboratory finds the messenger RNA reduced in fat of obese mice and people 2.Oct 1996Seen
GBP28 from human plasma
A Tokyo group purifies the protein from blood by its affinity for gelatin 5.1998Explained
A head shaped like tumor necrosis factor
The crystal structure of the globular head shows the fold of the tumor necrosis factor (TNF) family of inflammatory signaling proteins 6.1999Explained
Named adiponectin
The Osaka group builds an antibody-based blood test (an enzyme-linked immunosorbent assay, ELISA) and reports lower levels in obesity 3.1999Explained
Proposed as a shield for arteries
The Osaka group reports that adiponectin damps inflammatory adhesion molecules on cultured cells lining human arteries and is lower in people with coronary artery disease 56.2000Explained
2001Explained
2003Explained
Receptors cloned
AdipoR1 and AdipoR2 are identified by expression cloning 9.2004Explained
High levels, fewer heart attacks
In a nested case-control study among 18,225 American men, the top fifth of adiponectin carries a relative risk of heart attack of 0.39 against the bottom fifth 57.2005Overturned
High levels predict death in heart failure
In 195 patients with chronic heart failure, the upper two thirds of adiponectin carry a hazard ratio of 3.23 for death against the lowest third, after adjustment that includes NT-proBNP, a blood marker of heart strain 24.2005Trial
2006Explained
APPL1, the partner inside the cell
An adaptor protein that binds the receptors' inner tails is found to carry adiponectin's signal in cultured cells 59.2006Explained
Low adiponectin presented as a cause
A major review states that hypoadiponectinemia appears to play an important causal role in insulin resistance and diabetes 60.2006Overturned
The heart link shrinks
A British cohort and a meta-analysis of seven prospective studies find only a weak association with coronary heart disease, odds ratio 0.84 (0.70 to 1.01) 61.2010Explained
T-cadherin holds it in the heart
In mice lacking T-cadherin, adiponectin no longer associates with heart muscle, its blood level rises sharply, and its protection against heart injury is lost 62.2013Overturned
Genetics finds no causal effect on diabetes
Mendelian randomization, which uses inherited gene variants as a natural experiment, finds in up to 80,691 people no causal link between genetically lower adiponectin and type 2 diabetes 26.2013Trial
AdipoRon in mice
An oral receptor agonist improves diabetes in mice 30.2015Explained
Receptor crystal structures
AdipoR1 and AdipoR2 are solved as a new class of seven-helix protein holding zinc 50.2016Overturned
No causal effect on coronary heart disease
Mendelian randomization does not support a causal role in coronary heart disease 28.2026Trial
First-in-human trial of (PEG)-BHD1028
In a phase 1 trial in 64 insulin-resistant adults, the injected receptor agonist (PEG)-BHD1028 is well tolerated; meal-stimulated C-peptide changes significantly but not in step with dose, and weight, triglycerides and inflammatory markers do not change consistently 35.
- Total adiponectin by antibody test (enzyme-linked immunosorbent assay, ELISA)An antibody sandwich test on serum or plasma, first built in Osaka in 1999 3.Research cohorts and drug trialsPredicts type 2 diabetes in prospective studies, relative risk 0.72 per one-unit step on a logarithmic scale 38, but in the Atherosclerosis Risk in Communities (ARIC) study the association weakened substantially once baseline fasting glucose was added 64.There is no gold-standard method for the protein or its multimers 66; women run higher than men 14,82; insulin lowers it acutely 20; and a high value in heart or kidney disease does not mean health 24,42.
- High-molecular-weight (HMW) adiponectin and the HMW ratioAssays designed to measure only the largest multimers, or gel separation of all forms 7,63.ResearchIn 298 hospital patients the HMW-to-total ratio identified insulin resistance better than total adiponectin, area under the curve 0.713 against 0.615 63.In two large prospective cohorts, total and HMW adiponectin predicted diabetes about equally 64,65; in the older adults of the Cardiovascular Health Study the two tracked each other almost perfectly, with a correlation coefficient of r = 0.94, where 1 would be perfect 65.
- Early-pregnancy adiponectin to predict gestational diabetesA single measurement before or early in pregnancy, proposed to decide who needs a glucose tolerance test 116.ResearchAcross 11 studies of 2,865 women, the test flagged 64.7 percent of those who went on to develop gestational diabetes (sensitivity) and correctly cleared 77.8 percent of those who did not (specificity); the area under the curve, a score from 0.5 (no better than chance) to 1.0 (perfect), was 0.78 116.The authors called for prospective evaluation, not routine use 116; a 2025 review in women with obesity rated the certainty of the adiponectin associations low or very low and judged biomarker-based risk stratification not yet feasible 118.
- Adiponectin as a prognostic marker in heart and kidney diseaseA high level predicts death in chronic heart failure and in some kidney cohorts 24,42.ResearchHazard ratio 3.23 for the upper two thirds in chronic heart failure 24; hazard ratio 1.03 for each microgram per milliliter in moderate-to-severe (stage 3-4) chronic kidney disease 42.A 2025 meta-analysis of 12 kidney-disease studies found no overall association, with results varying widely between studies 44; natriuretic peptides from a strained heart raise adiponectin 25, so it partly tracks NT-proBNP, although in chronic heart failure it still predicted death after adjustment for NT-proBNP 24.
Trimer, hexamer, high molecular weight: which shape does the work?
The chains do not circulate one at a time. Three wind together through their collagen stalks into a trimer; two trimers joined by a disulfide bond, a sulfur-to-sulfur link between cysteine amino acids, form a hexamer, also called the low-molecular-weight form; and larger assemblies form the high-molecular-weight, or HMW, form 7,49. In 2003 a Tokyo group showed that a simple gel run without heat or chemicals that break disulfide bonds separates the forms, that the cysteine near the start of the chain is required for anything larger than a trimer, and that a version of the protein lacking it could not activate AMP-activated protein kinase in liver cells 7.
Rare human mutations made the case that shape matters. Two mutations associated with diabetes and low adiponectin, G84R and G90S, in which a glycine at position 84 or 90 is replaced by arginine or serine, produced protein that could not form HMW multimers; two others, R112C and I164T, could not even assemble into trimers and were poorly secreted 7. One Japanese carrier of R112C had markedly low blood adiponectin 4. A 2026 review lists these, with G45R and R55C, among population-specific mutations of high impact that usually act by disturbing multimer assembly or gene expression 36.
The idea that the HMW form is the true hormone came largely from Scherer's laboratory. In 2004 it proposed an index, SA, the HMW share of the total, and reported that mice of the db/db strain, which are bred to be severely obese and diabetic, had lower SA than their normal littermates despite similar total adiponectin, and that people with type 2 diabetes had lower SA than insulin-sensitive people; that thiazolidinedione drugs raised SA in mice and humans; that changes in SA tracked improvements in liver insulin sensitivity while changes in total adiponectin correlated poorly in individuals; and that injected HMW adiponectin lowered blood glucose in mice in proportion to dose 49. In 2006 a Tokyo group, using a new ELISA it had built to measure the HMW form alone, found in 298 hospital patients that the HMW-to-total ratio identified insulin resistance better than total adiponectin, with an area under the curve of 0.713 against 0.615 63. T-cadherin, a binding protein described in the next section, holds only the hexamer and HMW forms 12.
The evidence was never one-directional. A year before the SA paper, the same laboratory had reported that trimers unable to form larger complexes, or normal protein chemically reduced, were significantly more potent at lowering serum glucose than the higher-order forms, and proposed that a reducing activity in serum releases the active form 8. And the large prospective studies that could have shown HMW adiponectin to be the better predictor did not. In a case-cohort study, which compares people who developed a disease with a random sample of the whole cohort, of 550 people who developed diabetes over up to nine years and 540 who did not, drawn from 9,740 participants in the Atherosclerosis Risk in Communities (ARIC) study, the top quarter of total and of HMW adiponectin carried nearly identical hazard ratios, 0.40 and 0.38, while the HMW share did worse 64. In 3,802 older Americans in the Cardiovascular Health Study, total and HMW adiponectin correlated at r = 0.94 and predicted diabetes comparably 65.
At its true strength, then, the HMW hypothesis rests on mouse injections and on cross-sectional or treatment studies of a few hundred people; for predicting diabetes in populations, measuring the HMW form has not added anything measurable over total adiponectin 49,63,64,65. A 2018 review of measurement methods gives the practical reason the question is hard to close: there is no gold-standard method for the isoforms, and techniques disagree 66.
| Form | How it is built | What binds it | What the evidence says |
|---|---|---|---|
| Trimer | Three chains wound through their collagen stalks 7 | Not T-cadherin 12 | Chemically reduced trimers were the most potent glucose-lowering form in one 2003 mouse study 8 |
| Hexamer (low molecular weight) | Two trimers joined by a disulfide bond near the start of the chain 7,49 | T-cadherin 12 | Makes up a larger share of the total in type 2 diabetes, because the HMW share (SA index) is lower, in small cohorts 49 |
| High molecular weight | Larger multimers that need the same disulfide bond 7 | T-cadherin 12 | Argued to be the active form from mouse and treatment studies 49; predicts diabetes no better than total in large cohorts 64,65 |
| Globular head alone | The head cut free by a protease; studied as gAcrp30 54 | AdipoR1 and AdipoR2 in cell studies 9 | Increased fat burning in mouse muscle; activated AMPK in mouse muscle but not liver 52,54 |
The words, defined
- Disulfide bond
- A covalent link between the sulfur atoms of two cysteine amino acids; it holds adiponectin trimers together into larger assemblies.
- High-molecular-weight (HMW) adiponectin
- The largest circulating assemblies of adiponectin, built from several trimers.
- SA index
- The share of total adiponectin present as the HMW form, proposed in 2004 as a better index of insulin sensitivity.
- Area under the curve
- A summary of how well a test separates two groups, from 0.5, no better than a coin toss, to 1.0, perfect.
- Hazard ratio
- How much faster an event, such as diabetes or death, occurs in one group than another over the same time; below 1 means less often.
- Correlation coefficient (r)
- A number from -1 to 1 describing how closely two measurements move together; 0 means no linear relation.
Receptors that are built backward, and that turned out to be enzymes
In 2003 Toshimasa Yamauchi, Takashi Kadowaki and colleagues at the University of Tokyo used expression cloning, introducing a library of genes into cells and picking out those that gained the ability to bind the hormone, to identify two adiponectin receptors: AdipoR1, abundant in skeletal muscle, and AdipoR2, mainly in liver 9. Both are predicted to cross the cell membrane seven times, like the large family of G-protein-coupled receptors, but the authors found them structurally and functionally distinct from that family 9; the group later showed that their starting end sits inside the cell, the reverse of the G-protein-coupled arrangement 10.
Mice lacking AdipoR1 lost the activation of AMP-activated protein kinase (AMPK) by adiponectin, mice lacking AdipoR2 had less signaling through PPAR-alpha, a receptor inside the cell nucleus that switches on fat-burning genes, and mice lacking both lost adiponectin binding altogether and developed fat accumulation in tissues, inflammation, oxidative stress (damage from reactive forms of oxygen), insulin resistance and marked glucose intolerance 67. A second set of knockout mice, made at AstraZeneca and published the same year, disagreed: mice lacking AdipoR1 were fatter with worse glucose tolerance, but mice lacking AdipoR2 were lean, resisted diet-induced obesity and handled glucose better 68. On that evidence the two receptors may even pull in opposite directions, and the papers cited here do not resolve the conflict between the two mouse lines 67,68.
In 2015 a team at RIKEN and the University of Tokyo solved crystal structures of human AdipoR1 and AdipoR2 at 2.9 and 2.4 angstroms and described a new class of receptor structure: seven membrane-crossing helices arranged differently from those of G-protein-coupled receptors, enclosing a large cavity in which three conserved histidines hold a zinc ion 50. In 2017 a group in Montpellier crystallized AdipoR2 with a free fatty acid bound inside, showed that it has an intrinsic ability, enhanced by adiponectin, to split ceramide into sphingosine, the lipid backbone of ceramide, and a free fatty acid, found the same activity in AdipoR1, and stated plainly that the activity is low and its enzymology not yet characterized 11.
That finding had been anticipated. In 2011 Scherer's group at the University of Texas Southwestern Medical Center in Dallas reported that adiponectin stimulates a ceramide-splitting activity associated with both receptors, increasing formation of sphingosine-1-phosphate, a product that protects cells from programmed death, and that this happens independently of AMPK 51. In mice, extra adiponectin protected insulin-making beta cells and heart muscle cells from induced death, its absence made them more vulnerable, and cells lacking both receptors accumulated ceramide and died more readily when exposed to the saturated fat palmitate 51. The authors offered this as a unifying mechanism for the hormone's many reported effects; it remains a proposal resting on cell and mouse work 11,51.
A third binding partner is not a signaling receptor at all. T-cadherin, found in 2004 by screening for cell-surface molecules that capture adiponectin, binds hexamers and HMW multimers but not trimers or the globular head, and only adiponectin made in eukaryotic cells, cells with a nucleus, implying that chemical modifications added after the chain is made are needed 12. It is anchored to the outer face of the membrane by a lipid tail and has no part inside the cell, so the authors proposed that it holds the hormone for some other signaling molecule 12. In mice, T-cadherin turned out to matter more than its passive design suggested: in animals lacking it, adiponectin no longer associated with heart muscle, its blood level rose sharply, and its protection against heart enlargement under pressure overload, when the heart must pump against raised resistance, and against heart-attack damage was lost 62. Its gene, CDH13 on chromosome 16, carries one of the two strongest genetic signals for blood adiponectin levels, alongside ADIPOQ itself 36. The mouse finding that losing T-cadherin raises blood adiponectin fits that signal, but the connection has not been tested in people 36,62.
Inside muscle, AdipoR1 activation was reported in 2010 to let calcium into the cell, switching on a chain of enzymes: calcium/calmodulin-dependent protein kinase kinase beta (CaMKK-beta), which responds to calcium; AMPK; and sirtuin 1 (SIRT1), which removes acetyl tags from other proteins 10. Together they increase PGC-1-alpha, a master regulator of mitochondria, the cell's power plants; mice lacking AdipoR1 in muscle had fewer mitochondria, fewer oxidative type I muscle fibers, insulin resistance and reduced exercise endurance 10. All of this signaling biology comes from mice and cultured cells 10,51,67.
Inside the cell, the receptors' inner tails bind an adaptor protein called APPL1, which has no enzyme activity of its own and instead brings other proteins together 59. In cultured cells, more APPL1 strengthened and less APPL1 weakened adiponectin's effects on fat burning and glucose uptake, and APPL1 also regulated the crosstalk between adiponectin's signal and insulin's 59. That crosstalk reaches a different family of receptors: insulin makes its own receptor attach phosphate to the amino acid tyrosine on itself, which makes the insulin receptor a tyrosine kinase 69. APPL1 had been found two years before its adiponectin role, by a group in Dresden studying endosomes, the small membrane sacs that carry material inward from the cell surface; in human cells it moved from those sacs to the nucleus in response to epidermal growth factor (EGF) 70, whose receptor, EGFR, had been shown in 1980 to attach phosphate to tyrosine 71. AdipoR2 has a further job, described without reference to the hormone: in human cells and in its roundworm counterpart, PAQR-2, it keeps cell membranes fluid when too many saturated fatty acids, which stiffen membranes, are supplied 72. All of these findings come from cells, membranes and worms, not from people 59,69,70,72.
The words, defined
- Expression cloning
- Finding a gene by putting many candidate genes into cells and selecting the cells that acquire a property, such as binding a hormone.
- G-protein-coupled receptor
- A large family of seven-pass membrane receptors that signal through G proteins; the adiponectin receptors resemble them in outline but are not members.
- AMPK (AMP-activated protein kinase)
- An enzyme that senses a fall in a cell's energy charge and switches on fuel-burning and switches off fuel-storing pathways.
- PPAR-alpha
- A receptor in the cell nucleus that, when activated, turns on genes for burning fatty acids.
- Ceramide
- A waxy lipid built from sphingosine and a fatty acid; in excess it promotes cell death.
- Sphingosine-1-phosphate
- A lipid made from ceramide's breakdown products that signals cells to survive.
- T-cadherin
- A cell-surface protein anchored by a lipid tail that binds the larger forms of adiponectin but cannot signal on its own.
- Knockout mouse
- A mouse engineered to lack a particular gene.
- Adaptor protein
- A protein without enzyme activity that links a receptor to the enzymes that carry its signal.
- Tyrosine kinase
- An enzyme that attaches a phosphate group to the amino acid tyrosine on a protein, switching that protein's activity; the insulin receptor and the EGF receptor are both of this kind.
- Endosome
- A small membrane-bound sac inside a cell that carries material, including receptors, taken in from the cell surface.
What it does in liver and muscle: the mouse evidence, and the human gap
The case that adiponectin is an insulin-sensitizing hormone was built in mice between 2001 and 2003. A single injection of purified protein raised blood levels two- to threefold and transiently lowered glucose, and in mice that were genetically obese, autoimmune diabetic, or made diabetic with the drug streptozotocin, it temporarily abolished high blood sugar without raising insulin; in isolated liver cells it made small amounts of insulin more effective at suppressing glucose output 40. In obese mice adiponectin lowered the fat stored inside muscle and liver and increased the expression of molecules for burning fat and dissipating energy in muscle 39. In lipoatrophic mice, which have almost no fat and are severely insulin resistant, physiological doses of adiponectin and leptin, the appetite hormone also made by fat, together completely reversed the insulin resistance, while either alone did so only partly 39.
The mechanism proposed in 2002 was AMPK. Globular and full-length adiponectin activated AMPK in mouse muscle, only the full-length form did so in liver, and with it came phosphorylation, the attachment of a phosphate tag that switches an enzyme on or off, of acetyl-CoA carboxylase, an enzyme that gates fat burning, more fatty-acid oxidation and glucose uptake in muscle cells, and a fall in the liver's glucose-making machinery; blocking AMPK with a dominant-negative mutant, a disabled copy that jams the normal enzyme, blocked each effect 52. Mice engineered to carry three times the normal blood adiponectin cleared fat from the blood faster, suppressed liver glucose output better under insulin, showed more AMPK activation in liver, and had more brown fat, the heat-producing kind 73.
Deleting the gene gave a less tidy picture. In 2002 three groups published adiponectin-deficient mice. The Osaka mice had delayed clearance of free fatty acids and severe insulin resistance, but only on a high-fat diet 41. The Tokyo mice had moderate insulin resistance with glucose intolerance despite normal weight gain, and twice the thickening of the artery's inner lining after a cuff injury 74. The mice from Baylor College of Medicine in Houston had normal glucose and insulin, normal glucose and insulin tolerance and normal clamp results, even after seven months of high-fat feeding, and burned more fat, not less, in muscle and liver 75. A fourth line, from Scherer's group in 2006, had severe insulin resistance confined to the liver, and thiazolidinedione drugs improved glucose tolerance less in obese mice lacking adiponectin 76.
The most striking mouse result pointed somewhere unexpected. When Scherer's laboratory made leptin-deficient obese mice that also overproduced adiponectin, the animals' glucose and insulin normalized and they became even more obese than their littermates, with more fat tissue but less triglyceride in liver and muscle 77. The authors proposed that adiponectin acts as a peripheral starvation signal that steers fat into fat tissue and away from organs where it does harm 77. On that reading, adiponectin may improve insulin sensitivity partly by making fat tissue a better place to store fat, not by making the animal thinner 77.
In people the evidence is correlational. In 144 Pima Indian and white adults studied with the hyperinsulinemic-euglycemic clamp, adiponectin correlated with insulin sensitivity at r = 0.59 and inversely with fasting insulin at r = -0.63, and these related to adiponectin more closely than body fat did 15. In 182 adults whose abdominal fat was measured by computed tomography (CT) scanning, insulin sensitivity was related to both intra-abdominal fat and adiponectin independently 14. Correlations of this kind cannot say which way the arrow runs, the question the genetic studies described later were designed to answer 26.
The words, defined
- Lipoatrophy
- Loss or absence of fat tissue; lipoatrophic mice are a model of human lipodystrophy.
- Leptin
- A hormone made by fat in proportion to fat mass that signals the brain about energy stores.
- Hyperinsulinemic-euglycemic clamp
- The reference test of insulin sensitivity: insulin is infused at a fixed rate and glucose at whatever rate keeps blood sugar steady; the more glucose needed, the more sensitive the person.
- Dominant-negative mutant
- A deliberately disabled version of a protein that blocks the normal version when both are present.
- Brown fat
- Fat tissue that burns fuel to make heat rather than storing it.
Why it is low in obesity, diabetes and fatty liver
Adiponectin falls as fat rises, though fat is its source 3. Spiegelman's group saw the drop in fat-tissue messenger RNA in obese mice and people in 1996 2; the Osaka group saw it in blood in 1999 3; and in 2000 they reported that, among adults matched for age and body mass index, men with type 2 diabetes and no coronary disease averaged 6.6 micrograms per milliliter against 7.9 in men without diabetes, and women 7.6 against 11.7, with lower values still in people who had both diabetes and coronary disease 16.
Why growing fat should make less of it is not fully explained. Tumor necrosis factor alpha, an inflammatory signal produced in excess in insulin-resistant states, suppresses the adiponectin gene's promoter, the switch region that controls it, in cultured fat cells 48. Insulin itself lowers blood levels acutely: during glucose clamps, levels fell below baseline in lean, obese and diabetic volunteers alike 20. Among Pima Indians, a population with a high propensity to obesity and type 2 diabetes, the differences between normal, impaired and diabetic glucose tolerance persisted after accounting for body fat but disappeared after accounting for insulin sensitivity or fasting insulin, which places the fall closer to insulin resistance than to fatness 15. In 182 adults scanned by CT, intra-abdominal fat, age and sex were the independent determinants of adiponectin 14.
Fatty liver shows the pattern with a twist. A 2011 meta-analysis of 27 studies with 2,243 people found that controls had higher adiponectin than people with simple fatty liver, by 3.00 micrograms per milliliter, and than people with steatohepatitis, fatty liver with inflammation and liver-cell injury, by 4.75 17. Whether the controls themselves had undergone liver biopsy explained much of the difference, and when they had, people with simple fatty liver had levels similar to controls; the authors concluded that low adiponectin may matter more for the progression from fat to inflammation than for fat itself 17. A larger prospective test has since been done: among 35,026 Korean adults followed for 17 years, those in the lowest fifth of adiponectin were diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD), the current name for fatty liver linked to metabolic risk factors, at 3.20 times the rate (2.08 to 4.92) of those in the highest fifth (17.21 micrograms per milliliter or more), with a stronger association in women 78. Diagnoses came from disease codes in records, and the design shows association, not cause 78.
Low levels predict diabetes. Among Pima Indians, 70 people who later developed type 2 diabetes were compared with 70 controls from the same long-running study, matched for body mass index, age and sex; those with high adiponectin developed diabetes at 0.63 times the rate of those with low adiponectin (incidence rate ratio 0.63, 95 percent confidence interval 0.43 to 0.92) 79. In a German nested case-control study, which compares people inside a followed cohort who developed the disease with matched people who did not, the top quarter of adiponectin had an odds ratio of 0.3 (0.2 to 0.7) for diabetes compared with the bottom quarter after adjustment for waist-to-hip ratio, body mass index, glycated hemoglobin and lifestyle 80. A 2009 meta-analysis of 13 prospective studies, studies that measured adiponectin first and then followed people forward, with 14,598 participants and 2,623 new cases found a relative risk of 0.72 (0.67 to 0.78) for each one-unit step on a logarithmic scale of adiponectin, a step that multiplies the level by a fixed factor rather than adding a fixed amount; the result was consistent in white, East Asian, Asian Indian, African American and Native American populations 38. In 30,045 Copenhagen residents the cumulative incidence of diabetes by age 70 was 3 percent in the highest quarter and 20 percent in the lowest 37. An umbrella review of meta-analyses placed low adiponectin among the risk factors for type 2 diabetes with robust observational evidence 81.
Robust association is not the same as cause. In the ARIC study the protective association of total and HMW adiponectin weakened substantially, and lost its graded pattern, once baseline fasting glucose was added to the analysis 64. That is what one would expect if adiponectin mostly reports insulin resistance that is already under way, and it is the question the genetic studies took up 26,46.
The words, defined
- Promoter
- The stretch of DNA in front of a gene where switches that turn the gene on or off act.
- Steatohepatitis
- Fatty liver with inflammation and liver-cell injury, the form that can progress to scarring; now called metabolic dysfunction-associated steatohepatitis.
- Confidence interval
- The range within which the true value probably lies given the size of the study; the figure in brackets after an estimate.
- Odds ratio and relative risk
- Two ways of comparing how often an outcome occurs in one group against another; 1 means no difference, below 1 means less often.
- Glycated hemoglobin
- The share of hemoglobin carrying glucose, a measure of average blood sugar over about three months.
- Umbrella review
- A review of published meta-analyses that grades how credible each association is.
- Log unit (logarithmic scale)
- A step on a scale in which each unit multiplies the level by a fixed factor rather than adding a fixed amount; used for measurements, like adiponectin, that vary several-fold between people.
Why it is high: women, leanness, weight loss and drugs
Women run higher than men. In 182 Seattle adults, women averaged 7.4 micrograms per milliliter against 5.4 in men 14, and in 579 adults studied in Osaka men were significantly lower, with no difference between women before and after menopause 82. Androgens, the male sex hormones, appear to explain at least part of the difference 82,83. In mice, castration raised adiponectin, testosterone lowered it in both intact and castrated animals, and testosterone reduced its secretion from cultured fat cells 82. In people the evidence is correlational: among lean German children and adolescents, boys' adiponectin fell as puberty advanced, in step with rising testosterone (r = -0.42), so that adolescent boys averaged 5.6 micrograms per milliliter against 7.1 in girls 83. Older age goes with higher levels, independently of fat and sex 14.
Losing weight raises it, even though the tissue that makes it shrinks. In 22 obese patients after gastric partition surgery, a 21 percent fall in body mass index came with a 46 percent rise in mean adiponectin, which the authors took as a sign that obesity holds its production under feedback inhibition 19; the Osaka group had reported significant rises after weight reduction in people with and without diabetes 16. A 2023 meta-analysis of 95 studies with 6,232 patients found significant increases after bariatric surgery, largest after one-anastomosis gastric bypass 84, and a 2026 dose-response meta-analysis of 59 studies found that sleeve gastrectomy produced an earlier rise than Roux-en-Y gastric bypass, with trajectories that were not straight lines over time 85. In a 2024 analysis of a Copenhagen trial in which adults with obesity first lost weight on a low-calorie diet and then tried to keep it off with exercise, a drug that mimics the gut hormone glucagon-like peptide-1 (GLP-1), both, or placebo, adiponectin rose during maintenance with exercise and the drug combined, while growth differentiation factor 15 (GDF15), another hormone the authors grouped with it as a regulator of energy balance, rose only transiently during the initial diet 86.
Thiazolidinediones, diabetes drugs that act on PPAR-gamma, a nuclear receptor highly abundant in fat 20, produced the largest percentage rises of any intervention in the studies cited on this page 20,87. In 2001 the Osaka group showed that they increase the gene's activity and blood levels in insulin-resistant people and rodents without changing body weight, and that they counteract tumor necrosis factor's suppression of the promoter 48. In 2002, three months of troglitazone 600 milligrams a day more than doubled mean adiponectin in 27 volunteers, from 12.2 to 25.7 micrograms per milliliter, uniformly in lean, obese and diabetic participants, including lean people in whom the drug had no other measurable effect 20. That study had no placebo group, and troglitazone itself had already been withdrawn from the United States market, in March 2000, after reports of severe liver injury 45. For pioglitazone there is placebo-controlled evidence: in a randomized, double-blind trial in 26 people without diabetes who had familial combined hyperlipidemia, an inherited disorder of high cholesterol or triglycerides, 16 weeks of pioglitazone added to cholesterol-lowering treatment raised adiponectin by 156.2 percent in the treated group 87, and a meta-analysis published in 2023 of 39 randomized trials with 1,765 participants, designed to study fat distribution, found that thiazolidinediones raised adiponectin significantly compared with control treatments 88. In mice lacking adiponectin, thiazolidinediones improved glucose tolerance less, and their activation of AMPK in liver and muscle depended on adiponectin 76.
The incretin drugs raise it too, and it has been measured. A 2021 meta-analysis of 20 randomized trials with 1,497 people found that glucagon-like peptide-1 (GLP-1) receptor agonists, drugs that mimic a gut hormone released after meals, raised adiponectin by 0.59 micrograms per milliliter (0.10 to 1.08); liraglutide did so significantly and exenatide did not 89. A 2026 meta-analysis of randomized trials in type 2 diabetes found a pooled standardized increase of 0.30 (0.13 to 0.46) across 16 trials with 1,327 participants, with moderate to high heterogeneity; it pools the drug class 90. This page found no randomized estimate for semaglutide alone 90. Two studies without a comparison group measured it: in 65 Moscow patients with obesity, 26 of them with type 2 diabetes, adiponectin rose significantly (p < 0.001) over 8 months of semaglutide titrated to 1 milligram weekly 91, and in 54 Italian patients with type 2 diabetes who completed 12 months of dulaglutide or semaglutide, it also rose significantly 92. Without a comparison group, weight loss and the passage of time cannot be separated from the drug 91,92. Tirzepatide acts on the receptors for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), a second gut hormone that boosts insulin release after meals 21. In a post hoc analysis of SURMOUNT-1, its 72-week trial in people with obesity, adiponectin rose by 21.1, 35.1 and 47.7 percent more than with placebo at the 5, 10 and 15 milligram doses 21; an earlier analysis of a 26-week trial in type 2 diabetes had found increases with at least one dose 93. In phase 2 trials of survodutide, which acts on the glucagon and GLP-1 receptors, HMW adiponectin rose significantly over 46 weeks in people with obesity but did not change significantly over 16 weeks in people with type 2 diabetes 94. The tirzepatide and survodutide analyses were written wholly or partly by employees of the companies that make the drugs 21,93,94.
Two other drug classes raise it. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, diabetes drugs that make the kidney pass glucose into the urine, raised adiponectin compared with placebo by a standardized mean difference of 0.34 (0.23 to 0.45) in a 2024 meta-analysis of 38 randomized trials with 14,967 participants 22. An earlier meta-analysis of 14 trials with 2,142 people with type 2 diabetes found a similar 0.35 (0.24 to 0.46), clear in studies from Asia (0.42) but not significant in studies from Western countries (0.16) 95. Rimonabant, which blocks the cannabinoid-1 receptor, the brain's main receptor for the body's own cannabis-like signals, raised adiponectin at 20 milligrams a day by 57.7 percent by one method of analysis and 46.2 percent by another over a year in the RIO-Lipids trial of 1,036 overweight or obese people with abnormal blood fats on a reduced-calorie diet, a change the investigators judged partly independent of weight loss; depression and anxiety were among the commonest reasons people stopped the drug 23. It was later withdrawn from the European market because of depression and suicide 58. A drug that raised adiponectin by about half and was withdrawn for psychiatric harm is a reminder that the number is not the outcome 23,58.
Heart failure raises it by another route. Atrial and brain natriuretic peptides, hormones released by a stretched heart, increased adiponectin production in cultured human fat cells, and in 30 patients with chronic heart failure randomized to three days of intravenous atrial natriuretic peptide or saline, adiponectin rose from 6.56 to 7.34 micrograms per milliliter with the peptide and did not change with saline 25. Pregnancy, by contrast, lowers it, as a later section describes 96.
The words, defined
- Thiazolidinedione
- A class of diabetes drugs, including pioglitazone, rosiglitazone and troglitazone, that activate PPAR-gamma.
- PPAR-gamma
- A receptor in the nucleus of fat cells that controls fat-cell development and many fat-cell genes, including ADIPOQ.
- GLP-1 receptor agonist
- A drug that mimics glucagon-like peptide-1, a gut hormone that increases insulin release after meals and reduces appetite.
- Standardized mean difference
- An effect size without units, used to pool trials that measured the same thing in different ways; 0.2 is conventionally small and 0.5 moderate.
- Natriuretic peptides
- Hormones released by the heart when it is stretched; NT-proBNP, a fragment of one, is a standard blood test for heart failure.
- Post hoc analysis
- An analysis decided after a trial was designed, which can suggest but not establish an effect.
- Heterogeneity (I-squared)
- The share of the variation between studies in a meta-analysis that reflects real differences among them rather than chance; above 75 percent is considered high.
- SGLT2 inhibitor
- A diabetes drug that blocks sodium-glucose cotransporter-2 in the kidney, so that glucose is lost in the urine.
The adiponectin paradox: high levels and earlier death
If adiponectin were simply protective, people with the most of it should fare best. In several groups of sick or older people the reverse has been found. In 195 Danish patients with chronic heart failure followed for a median of 2.6 years, 46 died, and those in the upper two thirds of adiponectin had a hazard of death 3.23 times that of the lowest third after adjustment for age, blood pressure, a left ventricular ejection fraction below 25 percent (the share of blood the heart pumps out with each beat), duration of heart failure, kidney function and NT-proBNP 24. Adiponectin rose with NT-proBNP and fell with body mass index, and the authors suggested it was acting as a marker of wasting 24.
In 4,046 British men aged 60 to 79 followed for an average of six years, 734 died; among men without diagnosed cardiovascular disease or heart failure, the top third of adiponectin had a relative risk of death of 1.55 (1.19 to 2.02) compared with the bottom third, the estimate in men with heart failure was larger but imprecise, 2.37 (0.64 to 8.79), and adjusting for weight loss and kidney function changed little 43. In 820 people with stage 3 to 4 chronic kidney disease from the Modification of Diet in Renal Disease study, each microgram per milliliter more adiponectin carried a 3 percent higher risk of death from any cause and a 6 percent higher risk of cardiovascular death over about ten years 42.
The paradox is not uniform. A 2025 meta-analysis of 12 studies with 2,523 people with chronic kidney disease found no overall association between adiponectin and death, pooled unadjusted hazard ratio 1.003 per microgram per milliliter (0.981 to 1.025), with high heterogeneity; higher adiponectin went with higher mortality in studies outside Asia, in heavier populations and in populations with fewer women, but with lower mortality in people on peritoneal dialysis 44. That review was not registered in advance 44. A 2018 review described the overall relationship between adiponectin and mortality as U-shaped 66.
Newer cohorts extend the pattern beyond heart failure and kidney disease. A 2025 meta-analysis of five prospective studies of 3,225 people with stable coronary artery disease, followed for a median of 3.8 years, found an adjusted odds ratio for death of 2.51 (1.36 to 4.62) with higher adiponectin 97. Among 8,086 Chinese patients followed for five years after a first ischemic stroke, a stroke caused by a blocked artery, higher adiponectin went with more deaths from causes other than heart and blood-vessel disease, adjusted hazard ratio 1.47 (1.10 to 1.96), although the abstract prints p = 0.06 beside that interval; it did not go with cardiovascular death, a second stroke or poor recovery of function 98. In 448 people on hemodialysis, higher interleukin-6, an inflammatory signal, went with high adiponectin, and the authors summarized that markers of inflammation and malnutrition went with higher adiponectin, the pattern the wasting explanation below predicts 99. These are associations. The one genetic hint comes from a 2026 study of 8,599 older adults that measured thousands of blood proteins: its Mendelian randomization analysis named ADIPOQ among seven proteins with new, possibly causal links to heart failure or one of its subtypes at nominal significance, meaning a result that passed the usual statistical threshold without allowance for the many tests run; it found no evidence of colocalization, a check that the protein's genetic signal and the disease's come from the same variant, and the abstract does not give the direction of the effect 100.
Several explanations compete. The first is that the heart drives the number: natriuretic peptides raise adiponectin, so in heart failure a high adiponectin may partly be a second reading of a strained heart 25,46. The second is wasting: loss of weight and fat raises adiponectin, and wasting predicts death 19,24. The third is adiponectin resistance, the idea that receptors are reduced in insulin-resistant states so that more hormone has less effect 46,101. The fourth is that adiponectin itself does harm in some settings: in 356 Italians with type 2 diabetes, a gene variant that raises adiponectin was associated with higher cardiovascular mortality, incidence rate ratio 1.94 (1.23 to 3.07), which the authors read as a causal effect 102. That was one cohort with 58 deaths, and a 2018 review by the same Italian group concluded that none of these hypotheses rests on robust data 46,102. Reviews as recent as 2025 still describe the paradox as complicating any clinical reading of the number 103.
The words, defined
- Adiponectin paradox
- The finding that high adiponectin, expected to be protective, predicts higher mortality in heart failure, kidney disease and older age.
- NT-proBNP
- N-terminal pro-brain natriuretic peptide, a blood marker released by a strained heart and used to diagnose and grade heart failure.
- Wasting
- Involuntary loss of muscle and fat in chronic illness, which itself predicts death.
- Adiponectin resistance
- A proposed state in which tissues respond less to adiponectin, for example because receptor numbers fall.
- Peritoneal dialysis
- Kidney replacement in which fluid placed in the abdomen draws waste from the blood across the abdominal lining.
- Hemodialysis
- Kidney replacement in which blood is pumped through a filter outside the body, usually several times a week.
- Colocalization
- A genetic check of whether the same variant drives both a protein's level and a disease, which strengthens a Mendelian randomization result when it is found.
The reversal: genetics says marker, not shield
By the mid-2000s the leading view, stated in a 2006 review by the Tokyo group that had cloned the receptors, was that low adiponectin, produced by genetic variation together with obesity, appears to play an important causal role in insulin resistance, type 2 diabetes and the metabolic syndrome 60. The observational data in the previous sections cannot test that, because people with low adiponectin differ from people with high adiponectin in many ways, and because insulin resistance and insulin themselves lower adiponectin 15,20. Mendelian randomization is the method built for this problem: gene variants are allotted at conception and are not changed by later disease or lifestyle, so comparing people who inherited adiponectin-lowering variants with people who did not works as a natural experiment that is much less open to confounding and reverse causation 37.
The decisive study came in 2013. A large international consortium led from Exeter used variants in the ADIPOQ gene itself as instruments. Conventionally, each standard deviation (the typical spread of values around the average) lower adiponectin went with higher fasting insulin, lower insulin sensitivity and an odds ratio for type 2 diabetes of 1.75 (1.47 to 2.13) 26. Genetically, there was no causal association with fasting insulin in 29,771 people 26. For insulin sensitivity measured by gold-standard tests, there was only nominal evidence in 1,860 people, a result that passed the usual statistical threshold without allowance for the many tests run (-0.20 standard deviations, -0.38 to -0.02), and none in a larger score-based analysis of 2,969 people (-0.03, -0.07 to 0.01) 26. For type 2 diabetes the odds ratio was 0.94 (0.75 to 1.19) in 2,777 people with diabetes and 13,011 without, and across 15,960 people with diabetes and 64,731 without it was 0.99 (0.95 to 1.04) for each adiponectin-lowering allele, one inherited copy of a lowering variant 26. The authors concluded that their results provide no consistent evidence that raising adiponectin would improve insulin sensitivity or lower the risk of type 2 diabetes 26.
A genome-wide association study, which scans hundreds of thousands of common variants across all the chromosomes for links to a trait, published the year before, had already shown why the observational link might mislead 53. In 39,883 people of European ancestry it found ten loci, places in the genome, for adiponectin, and a score built from adiponectin-lowering variants at many genes, tested in consortium data on up to 121,335 people, was associated with higher diabetes risk, higher triglycerides, a higher waist-to-hip ratio and lower high-density lipoprotein (HDL) cholesterol, the fraction often called good cholesterol, but with lower body mass index 53. Variants outside ADIPOQ act on fat distribution and other metabolic traits at the same time, which is pleiotropy, one gene influencing several traits, and it biases Mendelian randomization when such variants are used as instruments 27,53.
The genetic verdict is not unanimous, and that should be said plainly. An analysis led from Copenhagen, totaling 756,219 people, reported two estimates 37. In the one-sample analysis, gene variants, adiponectin and diabetes were all measured in the same 96,903 Copenhagen residents, and the estimate was 1.13 (0.83 to 1.53) for each one-unit step down on a logarithmic scale of adiponectin, compatible with no effect 37. The two-sample analysis combined gene-to-adiponectin effects from one set of studies with gene-to-diabetes effects from others, 659,316 Europeans in all from international consortia and the UK Biobank, and gave 1.26 (1.01 to 1.57), which the authors said could represent a causal relationship 37. A Montreal study published online on 14 October 2026, using multi-ancestry genetic data, found that an apparent protective effect in its main analysis disappeared once variants linked to adiposity were removed or adiposity was adjusted for, leaving no causal association with type 2 diabetes; it raised the possibility that adiponectin carries part of the effect of visceral fat on diabetes in women 27.
The heart story began as hope. In 1999 the Osaka group reported that adiponectin damped the inflammatory adhesion molecules that let white blood cells stick to cultured cells lining human arteries, found lower levels in people with coronary artery disease, and suggested the measurement might help assess coronary risk 56. In 2004 a nested case-control study of 266 heart attacks or coronary deaths among 18,225 American male health professionals found a relative risk of 0.39 (0.23 to 0.64) for the top fifth of adiponectin against the bottom fifth, weakened to 0.56 (0.32 to 0.99) after adjustment for low-density and high-density lipoprotein cholesterol 57. Two years later the observational data themselves turned: in 589 British men with coronary events and 1,231 controls, the top third carried an odds ratio of 0.89 (0.67 to 1.18), and a meta-analysis of seven prospective studies with 1,318 cases gave 0.84 (0.70 to 1.01), an association the authors called comparatively moderate beside the strong one with diabetes 61. The genetic studies then tested cause directly, and for coronary heart disease their result is cleaner than for diabetes 28,29. A 2016 study using ADIPOQ variants as instruments estimated odds ratios per log unit of 0.83 (0.68 to 1.01) in 22,233 cases and 64,762 controls and 0.97 (0.84 to 1.12) in 63,746 cases and 130,681 controls, and an approach using variants from across the genome suggested protection that vanished after adjustment for known risk factors 28. A 2018 study found an inverse estimate by one method, 0.82 (0.71 to 0.94), that became null with methods robust to pleiotropy or when obesity-related variants were excluded, and found that coronary disease does not change adiponectin either 29. A 2022 study of four adipokines found no causal association between genetically predicted adiponectin and coronary disease, heart attack, atrial fibrillation, heart failure or stroke 104.
Taken together, the human genetics reverse the protective-hormone story: for type 2 diabetes and coronary heart disease, the best available evidence says that adiponectin mostly reflects metabolic health rather than producing it, with a residual possibility of a modest effect on diabetes that the two-sample estimate from the Copenhagen group keeps open 26,27,28,29,37,104. None of this disproves the mouse experiments, which changed the hormone abruptly, by injection, deletion or several-fold overproduction 40,41,73; it says that the natural differences in adiponectin between people do not explain their differences in diabetes or heart risk 26,28.
The words, defined
- Mendelian randomization
- Using inherited gene variants that shift a substance's level as a natural experiment to test whether the substance causes a disease.
- Instrument
- In Mendelian randomization, the gene variant or set of variants used to stand in for the exposure.
- Pleiotropy
- One gene variant affecting several traits; if it affects the disease by a route other than the exposure, it biases the analysis.
- Confounding
- A false association produced because a third factor, such as body fat, affects both the exposure and the outcome.
- Reverse causation
- When the disease, or its early stages, changes the exposure, rather than the other way around.
- One-sample and two-sample Mendelian randomization
- In a one-sample study the gene variants, the exposure and the disease are measured in the same people; a two-sample study takes the gene-to-exposure and gene-to-disease effects from different, usually much larger, sets of studies.
- Allele
- One of the alternative versions of a gene variant; each person carries two copies, one from each parent.
Drugs aimed at the receptors
If the hormone itself is a large, multi-part protein that is hard to give as a drug, a small molecule that switches on its receptors is the obvious alternative. In 2013 the Tokyo group reported AdipoRon, an orally active synthetic molecule that bound both AdipoR1 and AdipoR2 in test-tube studies, activated AMPK and PPAR-alpha pathways in muscle and liver as adiponectin does, improved insulin resistance and glucose intolerance in mice on a high-fat diet, lost those effects in mice lacking both receptors, and extended the shortened lifespan of genetically obese db/db mice on a high-fat diet 30. All of that was in mice 30. The 2015 receptor structures were presented explicitly as a basis for designing and improving such agonists 50.
ALY688 is a synthetic peptide, 10 amino acids long, that activates the adiponectin receptors; it is developed by Allysta Pharmaceuticals, whose employees are co-authors on several of the studies 31,105,106,107. In mice it improved glucose handling on a high-fat, high-sugar diet 108, prevented the fatty-liver inflammation and scarring of steatohepatitis without changing body weight 31, reduced heart enlargement, scarring and inflammation under pressure overload created by surgically narrowing the aorta 106, and prevented early scarring of the right ventricle in a mouse model of Duchenne muscular dystrophy, an inherited muscle-wasting disease 107. In 2026 a group at York University in Toronto reported that, given to rats during a heart attack or at the restoration of blood flow and then daily for 28 days, it reduced infarct size and troponin release and preserved heart function, with effects on immune cells in the heart and on the gut barrier 32. All of this is cell and animal work, apart from a test on human immune cells in a dish 105, and this page found no published human trial of ALY688 31,32,106,107,108.
In 2026 a group at India's Central Drug Research Institute in Lucknow reported two orally active small molecules, one that switches on AdipoR1 selectively and one that acts on both receptors; in rats whose muscles were wasted by a steroid drug or by cutting the nerve to a limb, each reduced the wasting and improved grip strength 33,34. Both were tested in cultured muscle cells and rats only, and no human data have been published 33,34.
In 2026 the first-in-human trial of (PEG)-BHD1028, an injected adiponectin receptor agonist carrying a polyethylene glycol (PEG) chain, was published 35. In this randomized, double-blind phase 1 study, adults with a body mass index of at least 27 and insulin resistance received single injections from 4 to 64 micrograms per kilogram, or daily injections for 28 days at 8, 16 or 32 micrograms per kilogram, in groups of eight of whom two received placebo, 64 people in all 35. The drug was well tolerated, with mild gastrointestinal side effects in 50 percent on drug and 33 percent on placebo 35. Over 28 days the C-peptide response to a test meal, a measure of how much insulin the pancreas secretes, changed by +25 percent on placebo and by -63, +24 and +2 percent at the three doses 35. The authors reported the difference between groups as statistically significant (p < 0.001) and concluded that it supports further development, but the changes do not follow the dose, insulin fell non-significantly, and there were no consistent changes in weight, triglycerides or inflammatory markers 35. The two authors are affiliated with a consultancy and with EncuraGen Inc., and the report is industry-authored 35. With 18 people on drug for four weeks, the trial establishes tolerability, not benefit 35.
The interventions that raise adiponectin in practice act indirectly: thiazolidinediones through PPAR-gamma, and incretin drugs alongside weight loss 20,21,48,90. A 2025 study in Cancer Cell pointed in an unexpected direction: in mice, locally produced adiponectin damped the colitis caused by cancer immunotherapy drugs called checkpoint inhibitors without blunting their effect on tumors, and in a prospective phase 1b/2 trial of 14 patients treated with extracorporeal photopheresis, a procedure that exposes a patient's white blood cells to light outside the body, the overall response rate of the immune-related side effects was 92 percent and every patient with colitis went into complete remission; the trial tested photopheresis, not adiponectin 109.
| Agent | What it is | Where tested | Result so far |
|---|---|---|---|
| Thiazolidinediones (troglitazone, withdrawn in 2000, and pioglitazone) | PPAR-gamma agonists that raise adiponectin production 48 | Humans and rodents 20,48,87,88 | Troglitazone roughly doubled adiponectin in 27 volunteers without a placebo group; pioglitazone raised it 156.2 percent in a small placebo-controlled trial; benefit reduced in mice lacking adiponectin 20,45,76,87 |
| gAcrp30 | The globular head as a drug, from Genset Corporation 54 | Mice 54 | Increased fat burning and weight loss in mice; no human data in the sources found 54 |
| AdipoRon | Oral small-molecule agonist of AdipoR1 and AdipoR2 30 | Mice 30 | Improved diabetes and extended lifespan of obese mice 30 |
| ALY688 | Synthetic receptor-agonist peptide, 10 amino acids long, developed by Allysta Pharmaceuticals 31,105 | Mice and rats 31,32,106,107,108 | Better insulin action, less fatty-liver inflammation and scarring, less heart remodeling under pressure overload and less heart scarring in a muscular-dystrophy model in mice; smaller heart-attack damage in rats; no published human trial found 31,32,106,107,108 |
| (PEG)-BHD1028 | Pegylated injectable receptor agonist 35 | Phase 1, 64 insulin-resistant adults 35 | Well tolerated; C-peptide changes significant but not dose-ordered; no consistent change in weight, triglycerides or inflammation 35 |
| CDRI-1709S and a medicarpin-based compound | Oral small molecules: an AdipoR1-selective agonist and an agonist of both receptors, from India's Central Drug Research Institute 33,34 | Rats 33,34 | Less muscle wasting after steroid treatment or nerve cutting, with better grip strength; no human data 33,34 |
The words, defined
- Agonist
- A drug that switches a receptor on, mimicking the natural signal.
- Phase 1 trial
- The first test of a drug in people, mainly to establish safety, tolerability and dosing.
- C-peptide
- A fragment released in equal amounts with insulin, used to measure how much insulin the pancreas makes.
- Pegylation
- Attaching polyethylene glycol chains to a drug to slow its removal from the body.
- Extracorporeal photopheresis
- A treatment in which a patient's white blood cells are separated, exposed to a light-activated drug and ultraviolet light, and returned.
- Infarct
- An area of tissue killed when its blood supply is cut off, as in a heart attack.
- Troponin
- A heart-muscle protein that leaks into the blood when heart cells die; its level measures heart-attack damage.
- Ischemia-reperfusion
- Loss of blood flow to a tissue followed by its restoration, which itself causes further injury.
- Colitis
- Inflammation of the colon.
Cancer: associations at their true strength
Because obesity raises the risk of several cancers and adiponectin falls with obesity, researchers have asked whether low adiponectin is part of the link. A 2023 meta-analysis of 32 observational studies found that people with colorectal cancer averaged 1.05 micrograms per milliliter less adiponectin than controls (-1.99 to -0.12), but the heterogeneity between studies was 95 percent and could not be explained, and the authors judged the evidence insufficient for any firm conclusion 110. A 2023 systematic review for breast cancer found that women with the highest adiponectin had a risk ratio of 0.76 (0.61 to 0.91) compared with the lowest, but Mendelian randomization did not support the association, and the certainty of the evidence ranged from very low to moderate 111.
The genetic test is again the most informative. Using 18 variants for adiponectin and data on 114,530 cancer cases and 245,284 controls, researchers at the International Agency for Research on Cancer found an apparent protective effect on colorectal cancer, odds ratio 0.90 per microgram per milliliter (0.84 to 0.97), that disappeared once horizontal pleiotropy, variants acting on cancer through other routes, was accounted for, and no association with pancreatic, kidney, ovarian or endometrial cancer 112. A 2025 Mendelian randomization study found no association between adiponectin and prostate cancer 113. A 2026 systematic review and meta-analysis of Mendelian randomization studies of ovarian cancer, covering work published to September 2023, reported that genetically higher adiponectin was associated with lower risk; its abstract gives no estimate for adiponectin, and the finding sits uneasily beside the null ovarian result above, so the question is best read as unsettled 112,114.
In laboratory studies adiponectin has been reported to act in opposite directions, both promoting and restraining inflammation and tumor growth, roles the colorectal review called dichotomous 110. The fair summary is that low adiponectin accompanies some cancers as it accompanies obesity, and that no human evidence found for this page shows that it causes them 110,111,112.
The words, defined
- Horizontal pleiotropy
- When a gene variant used in Mendelian randomization affects the disease through a route other than the exposure being tested.
Lipodystrophy: where the fat, and the hormone, are missing
Lipodystrophies are rare conditions, inherited or acquired, in which fat tissue is partly or wholly absent, accompanied by the metabolic complications of insulin resistance 18. In 2002 a Dallas group measured adiponectin in 93 patients: those with generalized lipodystrophy had markedly lower levels, medians of 1.5 micrograms per milliliter in 18 with the congenital form and 3.2 in 11 with the acquired form, than those with partial forms, 6.9 in 46 with the familial Dunnigan type and 7.9 in 18 with acquired partial lipodystrophy 18. Adiponectin correlated inversely with triglycerides and insulin and positively with HDL cholesterol, patients with diabetes had lower levels than those without, 3.0 against 7.1, and leptin followed the same pattern 18.
This is the clearest human condition in which adiponectin is extremely low, and it is where the mouse evidence is most directly relevant: in lipoatrophic mice, physiological doses of adiponectin and leptin together completely reversed insulin resistance, and either alone only partly 39. Outside lipodystrophy, true adiponectin deficiency comes from rare ADIPOQ mutations that prevent the chains assembling or leaving the cell 4,7,36. The studies found for this page report no trial of adiponectin replacement in people with lipodystrophy 18,39.
The words, defined
- Lipodystrophy
- A group of rare disorders with loss of fat tissue, generalized or partial, causing severe insulin resistance, high triglycerides and fatty liver.
- Dunnigan type
- Familial partial lipodystrophy, an inherited form in which fat is lost from the limbs and trunk.
Pregnancy and gestational diabetes
Pregnancy lowers adiponectin. In lean women studied before conception and again late in pregnancy with glucose clamps and fat biopsies, blood adiponectin fell from 13.5 to 9.9 micrograms per milliliter by 34 to 36 weeks, fat-tissue messenger RNA fell 2.5-fold, fat mass rose by about a quarter, and the changes tracked the fall in insulin's ability to drive glucose into tissues 96. Insulin infusion lowered HMW adiponectin before pregnancy, but that suppression was lost during pregnancy 96.
Gestational diabetes, diabetes first recognized in pregnancy, is preceded by lower adiponectin. A 2015 meta-analysis of nine prospective studies found that adiponectin in the first or early second trimester was 2.25 micrograms per milliliter lower (1.75 to 2.75) in women who later developed gestational diabetes 115. A 2016 meta-analysis of 11 studies with 2,865 women, 794 of whom developed it, estimated a sensitivity of 64.7 percent and a specificity of 77.8 percent for predicting it, area under the curve 0.78, with first-trimester values performing similarly 116. Those authors called for prospective testing of adiponectin combined with maternal characteristics to decide who needs a glucose tolerance test, not for its routine use 116. In a direct comparison, a Shanghai nested case-control study of 100 women who developed gestational diabetes and 100 who did not measured total and HMW adiponectin at 11 to 14 weeks alongside other markers and routine first-trimester blood tests 117. Across five statistical and machine-learning models, the markers chosen every time were fasting glucose and insulin-like growth factor binding protein 2 (IGFBP-2), a protein that carries a growth factor in the blood; a model using those two alone reached an area under the curve of 0.80 in a test set of 30 pairs, and adding further markers did not improve it 117.
A 2025 systematic review of 49 studies in women with obesity found that adiponectin was the only biomarker with enough data to meta-analyze for the composite adverse outcome; lower levels were associated with gestational diabetes and with pre-eclampsia, but the certainty of evidence was low or very low, and the authors concluded that biomarker-based risk stratification is not currently feasible 118.
The words, defined
- Gestational diabetes
- Diabetes first recognized during pregnancy, usually diagnosed with a glucose tolerance test in the second trimester.
- Sensitivity and specificity
- Sensitivity is the share of people who will develop the condition whom the test flags; specificity is the share of people who will not whom the test correctly clears.
- Pre-eclampsia
- High blood pressure with organ damage arising in the second half of pregnancy.
The blood test: what it measures, and why no guideline asks for it
Adiponectin is measured by immunoassay, usually ELISA, on serum or plasma 3,63. Total adiponectin assays count all forms together; HMW assays are designed to measure only the largest multimers; and research laboratories separate the forms on gels 7,63. A 2018 review of the methods found no gold standard for the isoforms and attributed much of the conflict in the literature to the difficulty of measuring them 66.
There is no single reference range. The first healthy volunteers ran from 1.9 to 17.0, in the units discussed earlier 3; in Seattle, women averaged 7.4 and men 5.4 micrograms per milliliter 14; in Phoenix, white volunteers averaged 10.2 against 7.2 in Pima Indians 15; and in Copenhagen the medians of the lowest and highest quarters were 9.2 and 28.9 37. Sex, age, ancestry and method all shift the number 14,15,66. A level is also lowered acutely by insulin and raised by thiazolidinediones, incretin drugs and natriuretic peptides 20,21,25.
What it adds to simpler tests is small. Insulin resistance is usually estimated from fasting glucose and insulin by HOMA-IR, the homeostasis model assessment of insulin resistance, or measured directly by clamp 15,65. In the older adults of the Cardiovascular Health Study, adiponectin's association with diabetes persisted after adjustment for HOMA-IR 65, but in ARIC adding fasting glucose largely removed the graded association 64, and the 2006 study that reported better prediction from the HMW ratio was cross-sectional, in 298 hospital patients 63. In pregnancy, the best pooled estimate of predictive accuracy is an area under the curve of 0.78 116; a 2025 review in women with obesity rated the certainty of adiponectin's associations with gestational diabetes low or very low 118. The most favorable recent estimate comes from the Framingham Offspring Study 119. Among 2,416 adults without diabetes followed for 10 years, 166 of whom developed it, a model containing fasting glucose, body mass index, the logarithm of adiponectin, glycated albumin (a measure of average blood sugar over the previous few weeks), parental diabetes, triglycerides and use of cholesterol-lowering drugs separated future cases with a C statistic, equivalent to the area under the curve, of 0.924, against 0.876 for fasting glucose alone; the authors themselves called fasting glucose alone an excellent predictor 119. The abstract does not isolate adiponectin's own contribution, and several authors are affiliated with Boston Heart Diagnostics, a commercial diagnostics company 119.
This page found no clinical practice guideline that recommends measuring adiponectin to diagnose or manage diabetes, cardiovascular disease, fatty liver or pregnancy. The reasons are visible in the evidence: the assays are not standardized 66; in one large cohort its graded association with diabetes largely disappeared once fasting glucose was added 64, though in another it persisted after HOMA-IR 65; its meaning reverses in heart and kidney disease 24,42; and because the genetics do not support a causal role, raising it is not a treatment target in its own right 26.
The words, defined
- ELISA
- Enzyme-linked immunosorbent assay: antibodies fixed to a plate capture a protein, and a second antibody linked to an enzyme produces a measurable color.
- HOMA-IR
- Homeostasis model assessment of insulin resistance, a number calculated from fasting glucose and fasting insulin.
- Reference range
- The range of values found in a defined healthy population, used to judge whether a result is unusual.
Supplements and diets that claim to raise it
Because adiponectin was cast as a protective hormone, raising it became a selling point. The genetic evidence undercuts the premise: if adiponectin levels do not cause diabetes, a product that raises the number would not by that route lower diabetes risk 26. The trials can still be read for what they show about the number itself.
Fish oil has the most careful data. A 2013 meta-analysis of 14 placebo-controlled trials, with 682 people taking fish oil and 641 taking placebo, found a rise of 0.37 micrograms per milliliter (0.07 to 0.67), but heterogeneity was high, the funnel plot, a check for whether small positive trials are overrepresented, was asymmetric, and a correction for that asymmetry gave 0.18 (-0.15 to 0.52), no longer significant; eating fish showed no effect in two small trials 120.
Curcumin, from turmeric, raised adiponectin in a 2023 meta-analysis of 13 trials by a standardized mean difference of 0.86 (0.33 to 1.39), but with heterogeneity of 93.1 percent 121. Flaxseed did not significantly change it across 13 trials 122; probiotics and synbiotics did not across 32 trials in prediabetes and type 2 diabetes 123; vitamin E did not overall across 10 trials, with a positive signal only in subgroups 124; and garlic did not across six small trials, although the authors of that review nonetheless wrote that garlic boosts adiponectin levels in general, a conclusion their own pooled estimate does not support 125.
Diets have been tested too, and the pooled trials are mostly null 126,127,128,129. Low-carbohydrate diets did no better than low-fat diets for adiponectin across 25 randomized trials with 2,222 adults 126. Time-restricted eating, eating only within a set window of hours each day, changed it by a standardized mean difference of 0.07 (-0.40 to 0.54) across six comparisons from randomized and non-randomized studies 127. Fasting regimens of several kinds raised it by 0.41 micrograms per milliliter (-0.07 to 0.89) across 16 reports, an estimate whose interval includes no change, though the authors called it marginally significant 128, and ketogenic diets, very low in carbohydrate, had no discernible effect across 22 trials 129. In type 2 diabetes, a 2022 meta-analysis of 10 randomized trials found that Mediterranean, Diabetes Prevention Program and Diabetes UK healthy-eating patterns raised it by a standardized mean difference of 0.81 (99 percent confidence interval 0.06 to 1.56), but with heterogeneity of 96 percent and evidence the authors rated of low to moderate quality 130. Alcohol raises it: across interventional studies in adults without known heart disease, drinking increased adiponectin by 0.56 milligrams per liter, the same as micrograms per milliliter (0.39 to 0.72) 131. That review's authors read such marker changes as indirect support for a protective effect of moderate drinking 131; because the genetic evidence does not make adiponectin a cause of diabetes or heart disease, a rise from drinking says nothing about benefit 26,28.
The interventions with large and reproducible effects are weight loss, by surgery or drugs, and thiazolidinediones 19,20,21,84,87. On the genetic evidence, what matters in weight loss is the improvement in fat and insulin sensitivity, of which a higher adiponectin is a reading 15,26.
The words, defined
- Funnel plot
- A chart of each trial's effect against its size; if small trials with large effects are overrepresented, the plot is lopsided, suggesting publication bias.
- Publication bias
- The tendency for positive results to be published more readily than null ones, which inflates pooled estimates.
What was believed and is not, and what is still unknown
Several beliefs about adiponectin have been overturned or substantially revised. It was believed that low adiponectin is a cause of type 2 diabetes 60; Mendelian randomization in tens of thousands of people mostly finds that it is not, with one large analysis leaving room for a modest effect 26,27,37. It was believed to protect against coronary heart disease 56,57; by 2006 a meta-analysis had already found the association weak 61, and the genetic studies find no causal effect 28,29,104. It was believed that more adiponectin is always better 46; in heart failure, kidney disease and older men higher levels predict earlier death, though not consistently across kidney studies 24,42,43,44. It was believed that the HMW form is the active hormone and the better test; in large cohorts it predicts diabetes no better than the total 49,64,65. Two drugs that raised it were withdrawn: troglitazone for liver injury and rimonabant for depression and suicide 20,23,45,58. And the receptors, cloned as signaling receptors, turned out to have enzyme activity as well, real but low 9,11,51.
What is established: the gene, the protein's domains and its assembly into multimers 4,5,7; that fat cells make it and that blood levels fall with obesity and insulin resistance and rise with weight loss and thiazolidinediones 3,15,19,20,87; the two AdipoR receptors and T-cadherin 9,12; potent insulin-sensitizing effects of manipulating it in mice 39,40,77; and its robust association with future diabetes 38,81.
What is not known. Why growing fat makes less of it 15,48. Whether AdipoR2 helps or harms metabolism, given knockout mice with opposite results 67,68. What explains the paradox, and whether high adiponectin ever does direct harm 46,102. Whether any receptor agonist works in people, which the first phase 1 trial, with changes that did not follow the dose, has not answered 35. And whether the residual signal in the largest two-sample Mendelian randomization analysis reflects a small true effect or bias 27,37. The genetic method itself needs care: two small two-sample analyses published within a year of each other reach opposite conclusions on Alzheimer's disease: one found no causal association (odds ratio 0.852, 0.586 to 1.117) 132, and the other a protective one (0.79, 0.65 to 0.96), using the 2012 genome-wide study of 39,883 Europeans for its adiponectin variants 53,133.
None of the papers cited on this page carries a retraction or expression of concern in its PubMed record as of the review date. Commercial interests are noted where the authors' affiliations show them: Genset Corporation for the globular fragment 54, AstraZeneca for the opposing receptor knockouts 68, Eli Lilly for the tirzepatide analyses 21,93, Boehringer Ingelheim for survodutide 94, EncuraGen for the first human agonist trial 35, Allysta Pharmaceuticals, developer of ALY688, whose staff co-authored several of the ALY688 studies 31,105,106,107, and Boston Heart Diagnostics for the Framingham risk model 119.
Where it connects
In the Atlas
Topics on the map
- Leptin
- Leptin resistance
- FGF21
- Insulin resistance
- Adipose expandability
- Lipodystrophy
- Brown adipose tissue
- Visceral adiposity
- GLP-1
- Semaglutide
- Tirzepatide
- AMPK
- PPAR-gamma and RXR
- HOMA-IR
- MASLD (fatty liver)
- Metabolic syndrome
- Ceramide score
- Testosterone
- TNF-α
- HDL
- Triglycerides
- Fasting glucose
- HbA1c
- Omega-3 (EPA/DHA)
- Curcumin
- Garlic (allicin)
- Vitamin E
- C-peptide
- GIP
- The incretin effect
- Beige fat
- UCP1
- Sirtuins
- Oral glucose tolerance test
- Fasting insulin
- Sarcopenia
- IL-6
- The J-curve
- The endocannabinoid system
On the map
A star in Fat as an organ, one of 11. The one adipokine that goes DOWN as fat mass goes up, which is why it behaves like a protective signal rather than a burden signal.
Sources
133 sources, numbered as they are cited. Every one was checked against PubMed or its publisher before it was cited here; the note under each says what it shows and what it does not.
- 1Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes.doi:10.1074/jbc.270.45.26746 · PMID 7592907
The Acrp30 paper from the Whitehead Institute: a 30 kDa secreted protein made only in mouse fat cells, messenger RNA induced more than 100-fold during differentiation, similar to C1q, forms large oligomers, secretion enhanced by insulin. Cell-culture work; no function shown.
- 2Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity.doi:10.1074/jbc.271.18.10697 · PMID 8631877
AdipoQ by differential display: 247 amino acids in mouse, signal sequence, collagenous Gly-X-Y region, globular domain like C1q, collagen X and cerebellin; expressed only in mature fat cells; messenger RNA reduced in fat of obese mice and humans. Function unknown at the time.
- 3Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.doi:10.1006/bbrc.1999.0255 · PMID 10092513
Names the apM1 product adiponectin, builds an ELISA, reports a healthy range printed as 1.9 to 17.0 mg/ml (the group's later papers use micrograms per milliliter), and lower levels in obese than non-obese subjects. Cross-sectional.
- 4Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin.doi:10.1038/sj.ijo.0801244 · PMID 10918532
Gene spans 17 kb on 3q27 with three exons and two introns; R112C carrier markedly low; exon 2 G/T polymorphism not associated with levels in 219 Japanese adults.
- 5Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma.doi:10.1093/oxfordjournals.jbchem.a021483 · PMID 8947845
Purified about 50 micrograms from 500 mL of human plasma by gelatin affinity; about 420 kDa on gel chromatography, 28 kDa reduced and 68 kDa non-reduced; identical to the apM1 product; 244 amino acids with signal sequence, non-helical region, 22 collagen repeats and globular domain.
- 6Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor.doi:10.1016/s0960-9822(98)70133-2 · PMID 9512423
Homotrimeric globular fragment at 2.1 angstroms with the folding topology of the TNF family; argues a shared ancestry of C1q-like proteins and TNFs.
- 7Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin.doi:10.1074/jbc.M300365200 · PMID 12878598
Non-reducing, non-heated gels separate trimers, hexamers and HMW multimers; an N-terminal cysteine disulfide is needed above the trimer; the Cys-Ser mutant lost AMPK activation in hepatocytes; G84R and G90S fail to form HMW, R112C and I164T fail to form trimers and are poorly secreted.
- 8Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity.doi:10.1074/jbc.M207198200 · PMID 12496257
Female mice have more HMW; insulin lowers HMW; oligomers need a Cys-39 disulfide; trimeric C39S mutant or reduced wild-type protein was more potent at lowering glucose than higher oligomers. Mouse and hepatocyte work; cuts against the later HMW-is-active view. Title typo as published.
- 9Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.doi:10.1038/nature01705 · PMID 12802337
Expression cloning of AdipoR1 (skeletal muscle) and AdipoR2 (liver); seven predicted transmembrane domains but structurally and functionally distinct from G-protein-coupled receptors; mediate AMPK, PPAR-alpha, fatty-acid oxidation and glucose uptake in cells.
- 10Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1.doi:10.1038/nature08991 · PMID 20357764
Receptors have the N-terminus inside the cell, opposite to GPCRs; AdipoR1 triggers calcium influx, CaMKK-beta, AMPK, SIRT1 and PGC-1alpha; muscle AdipoR1 knockout reduced mitochondria, type I fibers, insulin sensitivity and endurance. Mice and cells.
- 11Vasiliauskaité-Brooks I, Sounier R, Rochaix P, et al. Structural insights into adiponectin receptors suggest ceramidase activity.doi:10.1038/nature21714 · PMID 28329765
AdipoR2 crystallized with a free fatty acid; intrinsic basal ceramidase activity enhanced by adiponectin; revised AdipoR1 structure also has activity. The authors state the activity is low and its enzymology not yet characterized.
- 12Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin.doi:10.1073/pnas.0403382101 · PMID 15210937
Expression cloning finds T-cadherin binds hexameric and HMW adiponectin but not trimeric or globular forms, only when made in eukaryotic cells; GPI-anchored without an intracellular domain, proposed as a co-receptor. Cell studies.
- 13Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).doi:10.1006/bbrc.1996.0587 · PMID 8619847
The Osaka cloning of apM1, the most abundant transcript in human fat. PubMed carries no abstract; the title is the source for the name and its meaning.
- 14Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.doi:10.1007/s00125-003-1074-z · PMID 12687327
182 Seattle adults with CT fat measurement: women 7.4 vs men 5.4 micrograms/mL; adiponectin determined by intra-abdominal fat, age and sex; correlates with HDL (r=0.605).
- 15Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.doi:10.1210/jcem.86.5.7463 · PMID 11344187
23 white and 121 Pima adults with clamps: adiponectin correlates with insulin sensitivity (r=0.59) and fasting insulin (r=-0.63); group differences vanish after adjusting for insulin sensitivity or insulin. Cross-sectional.
- 16Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.doi:10.1161/01.atv.20.6.1595 · PMID 10845877
Age- and BMI-matched adults: diabetes without coronary disease 6.6 vs 7.9 micrograms/mL in men and 7.6 vs 11.7 in women; lower still with coronary disease; weight reduction raised levels. Cross-sectional and small.
- 17Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.doi:10.1016/j.metabol.2010.09.003 · PMID 21040935
27 studies, 2,243 people: controls higher than simple fatty liver by 3.00 and than NASH by 4.75 micrograms/mL; with biopsied controls, simple fatty liver similar to controls; low levels may matter for progression to NASH.
- 18Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies.doi:10.1210/jcem.87.5.8624 · PMID 11994394
93 patients: medians 1.5 (congenital generalized), 3.2 (acquired generalized), 6.9 (Dunnigan partial) and 7.9 (acquired partial) micrograms/mL; inverse with triglycerides and insulin; 3.0 vs 7.1 with vs without diabetes. Cross-sectional.
- 19Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin.doi:10.1210/jcem.86.8.7741 · PMID 11502817
22 obese patients after gastric partition surgery: 21% fall in BMI, 46% rise in mean adiponectin. Small, uncontrolled.
- 20Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.doi:10.2337/diabetes.51.10.2968 · PMID 12351435
27 volunteers, troglitazone 600 mg/day for 3 months: adiponectin 12.2 to 25.7 micrograms/mL uniformly, including lean subjects; insulin clamp lowered levels. Uncontrolled; troglitazone was withdrawn from the US market in March 2000.
- 21Sattar N, Linetzky B, Ruotolo G, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.doi:10.1016/j.jacc.2026.04.044 · PMID 42233927
392 randomly selected completers: at 72 weeks adiponectin +21.1%, +35.1%, +47.7% vs placebo at 5, 10, 15 mg; leptin and HOMA-IR fell. Post hoc; several authors are Eli Lilly employees.
- 22Buttice L, Ghani M, Suthakar J, et al. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.doi:10.1111/dom.15586 · PMID 38602398
38 RCTs, 14,967 participants, median 16 weeks: adiponectin vs placebo SMD 0.34 (0.23-0.45).
- 23Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.doi:10.1056/NEJMoa044537 · PMID 16291982
RIO-Lipids: 1,036 overweight or obese patients with untreated dyslipidemia on a hypocaloric diet, placebo or rimonabant 5 or 20 mg for 12 months: 20 mg raised adiponectin 57.7% (repeated measures) and 46.2% (last observation carried forward), partly independent of weight loss; depression, anxiety and nausea the commonest adverse events causing discontinuation.
- 24Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.doi:10.1161/CIRCULATIONAHA.104.530972 · PMID 16157772
195 patients with chronic heart failure, median 2.6 years, 46 deaths: upper two tertiles vs lowest HR 3.23 after adjustment including NT-proBNP; adiponectin rose with NT-proBNP and fell with BMI; authors suggest a marker of wasting.
- 25Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure.doi:10.1016/j.jacc.2009.02.038 · PMID 19477358
ANP and BNP raised adiponectin expression and secretion in human adipocytes; in 30 heart-failure patients randomized to IV ANP or saline, adiponectin 6.56 to 7.34 vs unchanged. A small trial, but direct evidence for one explanation of the paradox.
- 26Yaghootkar H, Lamina C, Scott RA, et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes.doi:10.2337/db13-0128 · PMID 23835345
ADIPOQ-variant instruments: no causal effect on fasting insulin (29,771), nominal effect on insulin sensitivity (1,860), none on type 2 diabetes (OR 0.94, 0.75-1.19; per allele 0.99, 0.95-1.04 in 15,960 cases and 64,731 controls). The central reversal.
- 27Legault SM, Gamache I, Belbellaj W, et al. The Causal Role of Adiponectin in Type 2 Diabetes across Ages and Sexes - An Observational and Mendelian Randomization Study.doi:10.1016/j.jcjd.2026.09.010 · PMID 42875002
Multi-ancestry two-sample MR: an initial protective estimate disappeared after removing adiposity-linked variants or adjusting for adiposity; network MR suggests adiponectin may mediate visceral fat's effect on diabetes in women. Volume and pages not yet assigned.
- 28Borges MC, Lawlor DA, de Oliveira C, White J, Horta BL, Barros AJD. Role of Adiponectin in Coronary Heart Disease Risk: A Mendelian Randomization Study.doi:10.1161/CIRCRESAHA.116.308716 · PMID 27252388
ADIPOQ-variant instruments: OR 0.83 (0.68-1.01) in CARDIoGRAM and 0.97 (0.84-1.12) in CARDIoGRAMplusC4D; genome-wide instruments attenuated to null after adjustment. Does not support a causal role.
- 29Au Yeung SL, Schooling CM. Adiponectin and coronary artery disease risk: A bi-directional Mendelian randomization study.doi:10.1016/j.ijcard.2018.03.132 · PMID 30041791
IVW OR 0.82 (0.71-0.94) but null with weighted median, MR-Egger or after excluding obesity-related variants; coronary disease does not change adiponectin. Authors: unlikely a cause, cannot completely rule out.
- 30Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.doi:10.1038/nature12656 · PMID 24172895
AdipoRon, an orally active small molecule binding AdipoR1 and AdipoR2; improves insulin resistance and glucose intolerance in high-fat-fed mice, lost in double-receptor knockouts; extends lifespan of db/db mice on high-fat diet. No human data.
- 31Huang Z, Sung HK, Yan X, et al. The adiponectin-derived peptide ALY688 protects against the development of metabolic dysfunction-associated steatohepatitis.doi:10.1111/cts.13760 · PMID 38847320
Human iPS-derived hepatocytes in vitro; in a mouse MASH diet model, ALY688-SR did not change body weight but reduced steatosis, inflammation and fibrosis. Three co-authors from Allysta Pharmaceuticals.
- 32Tang J, Sung HK, Lei Y, et al. ALY688 confers cardioprotection through macrophage TGFbeta-mediated Treg/Th17 dependent multi-organ responses.doi:10.1016/j.phrs.2026.108359 · PMID 42521105
Rat myocardial ischemia-reperfusion: the peptide receptor agonist ALY688, given at ischemia or reperfusion then daily for 28 days, reduced infarct size and troponin and preserved function. Animal only.
- 33Moin MR, Pal S, Das S, et al. Selective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.doi:10.1002/jcsm.70328 · PMID 42480512
CSIR-Central Drug Research Institute, Lucknow: an AdipoR1-selective agonist; cell work in HEK293T and C2C12 cells; oral 10 mg/kg/day in rat dexamethasone and denervation atrophy models restored muscle markers, grip strength and wire-hang time. Cell and animal work.
- 34Das S, Awasthi P, Moin MR, et al. A Novel Small-Molecule Dual Adiponectin Receptor 1/2 Agonist Induces Myogenesis and Ameliorates Skeletal Muscle Atrophy.doi:10.1002/jcsm.70364 · PMID 42635404
Same institute: a medicarpin compound (Med) activating AdipoR1 and AdipoR2; oral dosing attenuated atrophy in rat dexamethasone and denervation models and improved grip strength, wire hang and rotarod performance. Cell and animal work.
- 35Lapuerta P, Kim BB. A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of Adiponectin Agonist (PEG)-BHD1028 in People With Insulin Resistance.doi:10.1111/cts.70596 · PMID 42249891
First-in-human: single doses 4-64 micrograms/kg and 28-day daily doses 8-32 micrograms/kg, 8 per cohort with 2 on placebo; well tolerated; meal C-peptide change +25% placebo vs -63%, +24%, +2% (between-group p < 0.001 by the authors' test, not dose-ordered); insulin p = 0.116; no consistent change in weight, triglycerides or inflammation. 64 participants in eight cohorts; the authors conclude the results support further development. Authors affiliated with a consultancy and EncuraGen Inc.: industry-authored.
- 36Csép K. Genetic Determinants of Circulating Adiponectin Levels, a Complex Multifactorial Intermediate Phenotype.doi:10.3390/biom16101474 · PMID 42939728
2026 review: heritability 30-93% by design; strongest signals at ADIPOQ (chromosome 3) and CDH13, encoding T-cadherin (chromosome 16); rare high-impact missense mutations alter multimer assembly. Narrative review, single author.
- 37Nielsen MB, Çolak Y, Benn M, Nordestgaard BG. Low Plasma Adiponectin in Risk of Type 2 Diabetes: Observational Analysis and One- and Two-Sample Mendelian Randomization Analyses in 756,219 Individuals.doi:10.2337/db21-0131 · PMID 34426507
Copenhagen: lowest vs highest quartile (median 9.2 vs 28.9 micrograms/mL) HR 4.05; cumulative diabetes by 70 of 20% vs 3%; one-sample MR 1.13 (0.83-1.53), two-sample MR 1.26 (1.01-1.57). The main MR result that leaves room for a causal effect.
- 38Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis.doi:10.1001/jama.2009.976 · PMID 19584347
13 prospective studies, 14,598 participants, 2,623 cases: relative risk 0.72 (0.67-0.78) per 1-log microgram/mL; consistent across ancestries and assays. Observational; cannot separate cause from marker.
- 39Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.doi:10.1038/90984 · PMID 11479627
Mouse study: low adiponectin tracks insulin resistance; adiponectin lowers muscle and liver triglyceride in obese mice; in lipoatrophic mice adiponectin plus leptin completely reversed insulin resistance, either alone partly. Notes the 3q27 locus. Animal evidence only.
- 40Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.doi:10.1038/90992 · PMID 11479628
A single injection raised levels 2-3-fold and transiently lowered glucose; transiently abolished hyperglycemia in ob/ob, NOD and streptozotocin mice without raising insulin; enhanced insulin's suppression of glucose output in hepatocytes. Mouse and cell work.
- 41Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.doi:10.1038/nm724 · PMID 12068289
Osaka knockout mice: delayed free-fatty-acid clearance, high TNF-alpha, severe insulin resistance on a high-fat diet, reversed by viral re-expression of adiponectin. Mice.
- 42Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease.doi:10.1681/ASN.2006040331 · PMID 16885405
MDRD cohort, 820 patients with stage 3-4 CKD, 10 years: per 1 microgram/mL HR 1.03 (1.01-1.05) all-cause and 1.06 (1.03-1.09) cardiovascular death. Observational.
- 43Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure.doi:10.1001/archinte.167.14.1510 · PMID 17646605
4,046 British men aged 60-79, 734 deaths: without CVD or heart failure, top vs bottom third RR 1.55 (1.19-2.02) all-cause; heart failure 2.37 (0.64-8.79); no association with CVD without heart failure.
- 44Yang HS, Kim SN, Ro JH, Hur M. Adiponectin and All-Cause Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.doi:10.3390/metabo15040230 · PMID 40278358
12 studies, 2,523 patients: pooled HR per microgram/mL 1.003 (0.981-1.025), I2 79%; higher risk in non-Asian, higher-BMI and male-predominant studies, lower risk in peritoneal dialysis. Not prospectively registered.
- 45Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.doi:10.1023/a:1015895925374 · PMID 12141828
Case report; its abstract states that troglitazone was withdrawn from the US market in March 2000 because of severe hepatotoxicity. Cited for that fact.
- 46Menzaghi C, Trischitta V. The Adiponectin Paradox for All-Cause and Cardiovascular Mortality.doi:10.2337/dbi17-0016 · PMID 29263167
Review: prospective studies suggest adiponectin is a marker of glucose homeostasis without direct effect on diabetes or cardiovascular risk, yet positively related to mortality; explanations (adiponectin resistance, natriuretic peptides, genetics) none based on robust data.
- 47Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome.doi:10.1073/pnas.97.26.14478 · PMID 11121050
Genome scan of 2,209 people in 507 Caucasian families: a 3q27 locus linked to six metabolic-syndrome traits (lod 2.4-3.5). Linkage, not identification of ADIPOQ as the causal gene.
- 48Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.doi:10.2337/diabetes.50.9.2094 · PMID 11522676
Thiazolidinediones raise plasma adiponectin in insulin-resistant humans and rodents without changing weight, via the promoter; TNF-alpha suppresses the promoter in adipocytes and TZDs counteract it.
- 49Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.doi:10.1074/jbc.M311113200 · PMID 14699128
Proposes the SA index, HMW/(HMW+LMW); lower in db/db mice and type 2 diabetes; rises with thiazolidinediones; change in SA tracks hepatic insulin sensitivity while total adiponectin correlates poorly in individuals; HMW lowers glucose in mice. Small treatment cohorts; source of the HMW-is-active argument.
- 50Tanabe H, Fujii Y, Okada-Iwabu M, et al. Crystal structures of the human adiponectin receptors.doi:10.1038/nature14301 · PMID 25855295
AdipoR1 and AdipoR2 crystal structures at 2.9 and 2.4 angstroms: a novel receptor class, seven helices distinct from GPCRs, a large cavity with a zinc ion held by three conserved histidines. Structural work; presented as a basis for agonist design.
- 51Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.doi:10.1038/nm.2277 · PMID 21186369
Adiponectin stimulates a ceramidase activity associated with AdipoR1 and AdipoR2, raising sphingosine-1-phosphate independently of AMPK; protects mouse beta cells and cardiomyocytes from induced apoptosis. Mouse and cell work.
- 52Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.doi:10.1038/nm788 · PMID 12368907
AMPK activated by globular and full-length adiponectin in muscle and only by full-length in liver; ACC phosphorylation, fatty-acid oxidation, glucose uptake; dominant-negative AMPK blocks the effects. Mouse tissue and cells.
- 53Dastani Z, Hivert MF, Timpson N, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.doi:10.1371/journal.pgen.1002607 · PMID 22479202
ADIPOGen GWAS: 10 loci in 39,883 Europeans plus two multi-ethnic; an adiponectin-lowering score associated with more diabetes, triglycerides and waist-to-hip ratio, lower HDL, and lower BMI. Shows the pleiotropy that complicates MR.
- 54Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.doi:10.1073/pnas.98.4.2005 · PMID 11172066
The globular fragment gAcrp30 lowered post-meal free fatty acids, raised muscle fat oxidation, and caused sustained weight loss in high-fat/sucrose-fed mice without reducing food intake. First author's affiliation is Genset Corporation, which presented the fragment as a pharmacological compound: a commercial interest. Mice only.
- 55Straub LG, Scherer PE. Metabolic Messengers: Adiponectin.doi:10.1038/s42255-019-0041-z · PMID 32661510
Short review by the discoverer's group of adiponectin's history, sites and mechanisms of action and open questions.
- 56Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.doi:10.1161/01.cir.100.25.2473 · PMID 10604883
Osaka: physiological concentrations of adiponectin dose-dependently inhibited TNF-alpha-induced monocyte adhesion and VCAM-1, E-selectin and ICAM-1 expression on human aortic endothelial cells; plasma levels lower in coronary artery disease than in age- and BMI-adjusted controls; suggests measurement may help assess coronary risk. Cell work and a cross-sectional comparison: the origin of the protects-the-arteries idea.
- 57Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men.doi:10.1001/jama.291.14.1730 · PMID 15082700
Nested case-control study in 18,225 men of the Health Professionals Follow-up Study, 266 cases over 6 years: top vs bottom quintile RR 0.39 (0.23-0.64); 0.56 (0.32-0.99) after adjustment for LDL and HDL cholesterol. Observational.
- 58Yang P, Wang L, Xie XQ. Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.doi:10.4155/fmc.11.179 · PMID 22300098
Review; its abstract states that rimonabant, launched in 2006, was withdrawn from the European market because of suicide and depression as side effects. Cited for that fact.
- 59Mao X, Kikani CK, Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function.doi:10.1038/ncb1404 · PMID 16622416
Yeast two-hybrid screen with the AdipoR1 tail finds APPL1; overexpression increases and knockdown reduces adiponectin signaling, lipid oxidation, glucose uptake and GLUT4 translocation; APPL1 regulates crosstalk with insulin signaling. Cultured cells.
- 60Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.doi:10.1172/JCI29126 · PMID 16823476
Review stating that hypoadiponectinemia appears to play an important causal role in insulin resistance, type 2 diabetes and the metabolic syndrome: the view the later Mendelian randomization work tested.
- 61Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis.doi:10.1161/CIRCULATIONAHA.106.618918 · PMID 16894037
589 British men with coronary events and 1,231 controls: top vs bottom third OR 0.89 (0.67-1.18); meta-analysis of 7 prospective studies with 1,318 cases OR 0.84 (0.70-1.01); association comparatively moderate beside that with diabetes. The first observational reversal.
- 62Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice.doi:10.1172/JCI43464 · PMID 21041950
T-cadherin-null mice: adiponectin fails to associate with heart tissue and rises dramatically in the circulation; worse hypertrophy after pressure overload and larger infarcts after ischemia-reperfusion; adiponectin rescue ineffective without T-cadherin. Mice.
- 63Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome.doi:10.2337/dc05-1801 · PMID 16732021
298 hospital patients, the group's own new HMW ELISA: HMW-to-total ratio AUC 0.713 vs 0.615 for insulin resistance. Cross-sectional, selected patients.
- 64Zhu N, Pankow JS, Ballantyne CM, et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study.doi:10.1210/jc.2010-0716 · PMID 20719834
550 incident cases and 540 non-cases over 9 years: top quartile HR 0.40 total, 0.38 HMW, 0.65 ratio; attenuated substantially after fasting glucose. Total and HMW similar.
- 65Kizer JR, Arnold AM, Benkeser D, et al. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people.doi:10.2337/dc11-1519 · PMID 22148099
Cardiovascular Health Study, 3,802 older adults, 309 cases: total and HMW correlated r=0.94 and predicted diabetes comparably (HR per SD 0.49 and 0.42), persisting after HOMA-IR; associations plateau at high levels.
- 66van Andel M, Heijboer AC, Drent ML. Adiponectin and Its Isoforms in Pathophysiology.doi:10.1016/bs.acc.2018.02.007 · PMID 29655459
Review: isoforms act as acute-phase reactants; U-shaped association with mortality; conflicting data attributed to measurement difficulty and the lack of a gold standard.
- 67Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions.doi:10.1038/nm1557 · PMID 17268472
AdipoR1 knockout abolished adiponectin-induced AMPK activation; AdipoR2 knockout reduced PPAR-alpha signaling; double knockout lost binding and developed tissue triglyceride, inflammation, oxidative stress, insulin resistance and marked glucose intolerance. Mice.
- 68Bjursell M, Ahnmark A, Bohlooly-Y M, et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism.doi:10.2337/db06-1432 · PMID 17327425
AstraZeneca knockouts: AdipoR1-null mice fatter with worse glucose tolerance; AdipoR2-null mice lean, resistant to diet-induced obesity, better glucose tolerance. Contradicts the Tokyo double-knockout picture. Industry authors.
- 69Kasuga M, Zick Y, Blithe DL, Crettaz M, Kahn CR. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system.doi:10.1038/298667a0 · PMID 6178977
No abstract in PubMed; cited for the claim in its title: insulin makes its receptor phosphorylate itself on tyrosine, in rat liver membrane preparations.
- 70Miaczynska M, Christoforidis S, Giner A, et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment.doi:10.1016/s0092-8674(04)00117-5 · PMID 15016378
Max Planck Institute, Dresden: APPL1 and APPL2 are Rab5 effectors on a subpopulation of endosomes; in response to EGF and oxidative stress APPL1 moves from membranes to the nucleus; both are needed for cell proliferation. HeLa cells.
- 71Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.PMID 6157683
In membranes of A-431 human carcinoma cells, EGF-stimulated phosphorylation fell on tyrosine; the purified EGF receptor-kinase complex phosphorylated tyrosine itself. In vitro. No DOI registered.
- 72Devkota R, Svensk E, Ruiz M, Ståhlman M, Borén J, Pilon M. The adiponectin receptor AdipoR2 and its Caenorhabditis elegans homolog PAQR-2 prevent membrane rigidification by exogenous saturated fatty acids.doi:10.1371/journal.pgen.1007004 · PMID 28886012
paqr-2 mutant worms develop membrane rigidity and die on diets rich in saturated fat; human cells with AdipoR2 knocked down cannot counter palmitate's rigidifying effect. Worms and cultured cells.
- 73Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity.doi:10.1210/en.2003-1068 · PMID 14576179
Threefold higher adiponectin: faster lipid clearance, suppressed hepatic glucose output, more liver AMPK phosphorylation, more brown fat. Mice.
- 74Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation.doi:10.1074/jbc.C200251200 · PMID 12032136
Tokyo knockout mice: moderate insulin resistance and glucose intolerance in homozygotes despite normal weight gain; twice the neointimal formation after cuff injury. Mice.
- 75Ma K, Cabrero A, Saha PK, et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin.doi:10.1074/jbc.C200362200 · PMID 12151381
Baylor knockout mice: normal glucose, insulin, glucose and insulin tolerance and clamp, even after 7 months of high-fat diet; increased beta-oxidation. The knockout that disagreed.
- 76Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists.doi:10.1074/jbc.M505311200 · PMID 16326714
Knockout mice: severe hepatic but not peripheral insulin resistance on clamp; rapid glucose intolerance on high-fat diet; thiazolidinedione benefit and AMPK activation diminished without adiponectin. Mice.
- 77Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue.doi:10.1172/JCI31021 · PMID 17717599
ob/ob mice overexpressing adiponectin: normalized glucose and insulin while becoming more obese; less inflammation; proposes adiponectin steers triglyceride into fat and away from liver and muscle. Mice.
- 78Yang YS, Zhang HS, Kimm H, et al. Adiponectin as a Predictor of Metabolic Dysfunction-Associated Steatotic Liver Disease and Non-Alcoholic Fatty Liver Disease: A 17-Year Korean Cohort Study.doi:10.4093/dmj.2025.0007 · PMID 40916682
35,026 adults of the Korean Cancer Prevention Study-II biobank, 2004-2021, outcomes from ICD-10 codes: lowest vs highest quintile (17.21 micrograms/mL or more) HR 3.20 (2.08-4.92) for MASLD; stronger in women. Observational. Published online 8 September 2025.
- 79Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population.doi:10.1016/S0140-6736(02)09335-2 · PMID 12114044
Case-control within a Pima cohort, 70 cases and 70 matched controls: high adiponectin incidence rate ratio 0.63 (0.43-0.92). Association only.
- 80Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus.doi:10.1016/S0140-6736(03)12255-6 · PMID 12547549
German nested case-control study: 5.34 vs 6.87 micrograms/mL; top vs bottom quartile odds ratio 0.3 (0.2-0.7) after adjustment including HbA1c. Observational.
- 81Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses.doi:10.1371/journal.pone.0194127 · PMID 29558518
Umbrella review of 142 associations: decreased adiponectin among the risk factors with robust (observational) evidence for type 2 diabetes. Credibility grading, not causation.
- 82Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein.doi:10.2337/diabetes.51.9.2734 · PMID 12196466
442 men lower than 137 women, no pre- vs postmenopausal difference; castration raises and testosterone lowers adiponectin in mice; testosterone reduces secretion from 3T3-L1 adipocytes.
- 83Böttner A, Kratzsch J, Müller G, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels.doi:10.1210/jc.2004-0303 · PMID 15292348
Leipzig, 200 normal-weight and 135 obese children and adolescents: in lean boys adiponectin declined through puberty, inversely related to testosterone (r = -0.42); adolescent boys 5.6 vs girls 7.1 mg/L (equal to micrograms/mL). Cross-sectional.
- 84Huang J, Chen Y, Wang X, Wang C, Yang J, Guan B. Change in Adipokines and Gastrointestinal Hormones After Bariatric Surgery: a Meta-analysis.doi:10.1007/s11695-022-06444-8 · PMID 36607567
95 articles, 6,232 patients: adiponectin rises significantly after bariatric surgery, most after one-anastomosis gastric bypass; leptin falls. Mostly before-after studies.
- 85Ahmed MB, Khanafer Y, Abdelsalam MA, et al. Magnitude and durability of hormonal adaptations after bariatric surgery: a dose response meta-analysis.doi:10.1016/j.soard.2026.03.011 · PMID 41951541
59 studies modeling trajectories: sleeve gastrectomy produces an earlier rise in adiponectin than Roux-en-Y bypass; several hormones change nonlinearly.
- 86Fiorenza M, Checa A, Sandsdal RM, et al. Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids.doi:10.1016/j.xcrm.2024.101629 · PMID 38959886
Copenhagen adults with obesity after low-calorie-diet weight loss, then maintenance with exercise, GLP-1 analog, both, or placebo: GDF15 and C16:0-C18:0 ceramides rose transiently with the initial weight loss; with combined exercise and GLP-1 analog, FGF21 and leptin fell and adiponectin rose.
- 87Naoumova RP, Kindler H, Leccisotti L, et al. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.doi:10.1016/j.jacc.2007.07.070 · PMID 18021872
26 patients with familial combined hyperlipidemia on lipid-lowering therapy, pioglitazone 30 then 45 mg daily or placebo for 16 weeks: adiponectin +156.2% in the pioglitazone group; the placebo group showed no change in the main measures. Small randomized trial.
- 88Zhang F, Pan X, Zhang X, Tong N. The effect of thiazolidinediones on body fat redistribution in adults: A systematic review and meta-analysis of randomized controlled trials.doi:10.1111/obr.13675 · PMID 38098209
39 RCTs, 1,765 participants: thiazolidinediones improved glucose control, insulin resistance, adiponectin and lipids compared with controls (p < 0.05). Published online 14 December 2023.
- 89Simental-Mendía LE, Sánchez-García A, Linden-Torres E, Simental-Mendía M. Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.doi:10.1111/bcp.14855 · PMID 33835520
20 RCTs, 1,497 people: +0.59 micrograms/mL (0.10-1.08); liraglutide 0.55 (0.04-1.06), exenatide 0.60 (-0.23 to 1.42, not significant).
- 90Kanbay M, Shah E, AlShiab R, et al. Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.doi:10.1111/dom.71106 · PMID 42449480
41 RCTs in type 2 diabetes searched to February 2026: adiponectin SMD +0.30 (0.13-0.46) across 16 trials and 1,327 participants; moderate to high heterogeneity. Class-level, not drug-specific.
- 91Tyurina AV, Kurochkina NS, Yezhov MV. Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients.doi:10.18087/cardio.2026.2.n3116 · PMID 41925173
65 Moscow patients with obesity (26 with type 2 diabetes), semaglutide titrated to 1 mg weekly for 8 months: adiponectin rose (p < 0.001), leptin fell. No comparison group.
- 92Al Refaie A, Baldassini L, Mondillo C, et al. Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.doi:10.1007/s12020-024-04085-8 · PMID 39521749
65 Italian patients enrolled, 54 completed 12 months (30 dulaglutide, 24 semaglutide): adiponectin rose (p < 0.05). No comparison group. Published online 9 November 2024.
- 93Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.doi:10.1210/clinem/dgaa863 · PMID 33236115
Post hoc analysis of a 26-week phase 2 trial in 316 people with type 2 diabetes: adiponectin rose with one or more tirzepatide doses. All authors Eli Lilly employees.
- 94Ekinci EI, Maldonado SG, Unseld A, Martinez JA, Hennige AM, Schoelch C. Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.doi:10.1111/dom.70861 · PMID 42331726
Post hoc analysis of two phase 2 trials: HMW adiponectin unchanged over 16 weeks in type 2 diabetes, increased significantly over 46 weeks in overweight/obesity. Five of six authors are Boehringer Ingelheim employees.
- 95Wang Y, Xia N. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.doi:10.1055/a-1897-6121 · PMID 36049756
14 RCTs, 2,142 patients with type 2 diabetes: SMD 0.35 (0.24-0.46), I2 19%; studies from Asia 0.42, from Western countries 0.16 (not significant).
- 96Catalano PM, Hoegh M, Minium J, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism.doi:10.1007/s00125-006-0264-x · PMID 16752186
Lean women before and late in pregnancy with clamps and fat biopsies: 13.5 to 9.9 micrograms/mL; fat messenger RNA down 2.5-fold; fat mass up 25%; insulin's suppression of HMW lost in pregnancy.
- 97Jitta SR, Vatsavayi P, Tera CR, et al. Long-term prognostic role of adiponectin in stable coronary artery disease: A meta-analysis of prospective studies.doi:10.4330/wjc.v17.i6.105452 · PMID 40575429
5 prospective studies, 3,225 patients, median 3.8 years: adjusted OR for all-cause mortality 2.51 (1.36-4.62), I2 65.5%; major adverse cardiovascular events 1.04 (1.02-1.06).
- 98Chen S, Lin F, Yin J, et al. Association between elevated adiponectin levels and 5-year risk of clinical outcomes in patients with ischaemic stroke.doi:10.1136/svn-2024-003517 · PMID 41057170
8,086 Chinese patients with first ischemic stroke from 201 hospitals: higher adiponectin and 5-year non-cardiovascular mortality adjusted HR 1.47 (1.10-1.96), with p printed as 0.06; no association with cardiovascular death, recurrence or poor functional outcome. Observational.
- 99Bui TV, You AS, Kalantar SS, et al. Leptin and Adiponectin as Uremic Adipokines: Associations with Survival in a Prospective Hemodialysis Cohort.doi:10.3390/toxins17110525 · PMID 41295840
448 hemodialysis patients (MADRAD study): female sex, longer dialysis vintage, Black race, higher IL-6 and lower leptin associated with high adiponectin; markers of inflammation and malnutrition associated with lower leptin and higher adiponectin; a high leptin-to-adiponectin ratio associated with lower mortality. Observational.
- 100Njoroge JN, Sanders van Wijk S, Austin TR, et al. Large-Scale Proteomic Profiling of Incident Heart Failure and Its Subtypes in Older Adults.doi:10.1161/CIRCGEN.124.005031 · PMID 41636061
Cardiovascular Health Study and AGES-Reykjavik, 8,599 participants, ARIC replication: two-sample MR named ADIPOQ among seven new, possibly causal proteins for heart failure or a subtype at nominal significance, without evidence of colocalization; direction not given in the abstract. One co-author affiliated with Novartis.
- 101Francischetti EA, Dezonne RS, Pereira CM, et al. Insights Into the Controversial Aspects of Adiponectin in Cardiometabolic Disorders.doi:10.1055/a-1239-4349 · PMID 32927496
Narrative review of the paradox; links it to adiponectin resistance, the downregulation of receptors in insulin-resistant states. A hypothesis, not a demonstration.
- 102Ortega Moreno L, Copetti M, Fontana A, et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes.doi:10.1186/s12933-016-0339-z · PMID 26817832
Gargano Heart Study, 356 patients, 58 cardiovascular deaths: the adiponectin-raising rs822354 allele carried IRR 1.94 (1.23-3.07). One small cohort, single instrument; suggestive, not established.
- 103Kazemi T, Mao Y, Zhang T. The Cardioprotective Effects of Adiponectin in Diabetes.doi:10.1007/s11892-025-01610-5 · PMID 41082155
2025 narrative review: the adiponectin paradox complicates clinical interpretation in diabetes and heart failure.
- 104Chen D, Zhang Y, Yidilisi A, Xu Y, Dong Q, Jiang J. Causal Associations Between Circulating Adipokines and Cardiovascular Disease: A Mendelian Randomization Study.doi:10.1210/clinem/dgac048 · PMID 35134201
Two-sample MR of four adipokines: no causal association of genetically predicted adiponectin with coronary disease, myocardial infarction, atrial fibrillation, heart failure or stroke.
- 105Lone AH, Tang J, Pignalosa A, Hsu HH, Abdul-Sater AA, Sweeney G. A novel blood-based bioassay to monitor adiponectin signaling.doi:10.1016/j.intimp.2024.111890 · PMID 38547772
Describes ALY688 as a small 10-amino-acid peptide; in a mouse endotoxemia model and in human donor immune cells treated in a dish it activated AMPK and p38. Two co-authors from Allysta Pharmaceuticals.
- 106Cho S, Dadson K, Sung HK, et al. Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF).doi:10.1016/j.biopha.2023.116119 · PMID 38181714
Transverse aortic constriction in mice: ALY688 attenuated dysfunction, hypertrophy, fibrosis and inflammation. One co-author from Allysta Pharmaceuticals.
- 107Gandhi S, Delfinis LJ, Bhatt PD, et al. Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy.doi:10.1016/j.molmet.2025.102179 · PMID 40490137
Young D2.mdx mice: ALY688 prevented right ventricular and left atrial fibrosis, macrophage infiltration and mitochondrial stress. One co-author from Allysta Pharmaceuticals.
- 108Sung HK, Mitchell PL, Gross S, Marette A, Sweeney G. ALY688 elicits adiponectin-mimetic signaling and improves insulin action in skeletal muscle cells.doi:10.1152/ajpcell.00603.2020 · PMID 34910600
Rat L6 muscle cells: AMPK, ACC and p38 activation, better insulin signaling and glucose uptake; improved glucose handling in high-fat, high-sucrose-fed mice. Published online December 2021.
- 109Braun LM, Giesler S, Andrieux G, et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity.doi:10.1016/j.ccell.2025.01.004 · PMID 39933899
Mouse work implicating local adiponectin in damping checkpoint-inhibitor colitis while sparing anti-tumor T cells; a prospective phase 1b/2 trial of extracorporeal photopheresis in 14 patients (overall response rate of immune-related adverse events 92%, 95% CI 63.97-99.81; colitis complete remission 100%). The trial tested photopheresis, not adiponectin.
- 110Macleod A, Scheurlen KM, Burton JF, et al. Systemic adiponectin levels in colorectal cancer and adenoma: a systematic review and meta-analysis.doi:10.1038/s41366-023-01358-6 · PMID 37626126
32 observational studies: colorectal cancer 1.05 micrograms/mL lower (-1.99 to -0.12), I2 95% unexplained; authors judge evidence insufficient; notes dichotomous experimental roles.
- 111Lou MWC, Drummond AE, Swain CTV, et al. Linking Physical Activity to Breast Cancer via Inflammation, Part 2: The Effect of Inflammation on Breast Cancer Risk.doi:10.1158/1055-9965.EPI-22-0929 · PMID 36867866
Systematic review of 34 observational and 3 MR studies: highest vs lowest adiponectin RR 0.76 (0.61-0.91) for breast cancer, not supported by MR; certainty very low to moderate.
- 112Dimou NL, Papadimitriou N, Mariosa D, et al. Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.doi:10.1002/ijc.33338 · PMID 33038280
114,530 cases, 245,284 controls: colorectal OR 0.90 (0.84-0.97) per microgram/mL lost after accounting for pleiotropy; no association with pancreatic, renal cell, ovarian or endometrial cancer.
- 113Ji WT, Wang YK, Jin XF, Wang SQ, Wang Y. Evaluating the relationship between educational attainment, obesity-related indicators, and prostate diseases: A univariable and multivariable Mendelian randomization study.doi:10.1097/MD.0000000000046585 · PMID 41431082
Two-sample MR: genetically predicted adiponectin not associated with prostate cancer.
- 114Yalew M, Lumsden AL, Mulugeta A, et al. Risk factors of ovarian cancer: a systematic review and meta-analysis of Mendelian randomiation studies.doi:10.1093/pubmed/fdag034 · PMID 42127414
120 MR articles to 11 September 2023, 230 exposures: higher adiponectin associated with lower ovarian cancer risk; no adiponectin estimate in the abstract. Title misspelling as published.
- 115Bao W, Baecker A, Song Y, Kiely M, Liu S, Zhang C. Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: A systematic review.doi:10.1016/j.metabol.2015.01.013 · PMID 25749468
Nine prospective studies: first or early second trimester adiponectin 2.25 micrograms/mL lower (1.75-2.75) in women who later developed GDM.
- 116Iliodromiti S, Sassarini J, Kelsey TW, Lindsay RS, Sattar N, Nelson SM. Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis.doi:10.1007/s00125-015-3855-6 · PMID 26768001
11 studies, 2,865 women, 794 with GDM: sensitivity 64.7%, specificity 77.8%, AUC 0.78; first trimester similar (AUC 0.79). Calls for prospective evaluation, not routine use.
- 117Yang MN, Zhang L, Wang WJ, et al. Prediction of gestational diabetes mellitus by multiple biomarkers at early gestation.doi:10.1186/s12884-024-06651-4 · PMID 39285345
Shanghai Early Life Plan cohort, 100 GDM/control pairs, markers including total and HMW adiponectin at 11-14 weeks: fasting glucose and IGFBP-2 chosen by all five models; random forest with the two AUC 0.80 in a 30-pair test set; more predictors did not improve it.
- 118Wishlade T, Wetzler S, Aiken CE. Biomarkers predicting adverse pregnancy outcomes in women living with obesity: a systematic review and meta-analysis.doi:10.1016/j.xagr.2025.100527 · PMID 41019841
49 studies, 7,479 pregnancies with BMI of 30 or more: lower adiponectin associated with GDM (SMD -0.57) and pre-eclampsia (OR 0.65); certainty low or very low; risk stratification not yet feasible.
- 119Ai M, Otokozawa S, Liu CT, et al. Diabetes Mellitus Risk Prediction in the Framingham Offspring Study and Large Population Analysis.doi:10.3390/nu17071117 · PMID 40218874
2,416 non-diabetic adults followed 10 years, 166 cases: model with glucose, BMI, log adiponectin, glycated albumin, parental diabetes, triglycerides and lipid drugs C statistic 0.924 vs 0.876 for fasting glucose alone. Several authors affiliated with Boston Heart Diagnostics: a commercial interest.
- 120Wu JHY, Cahill LE, Mozaffarian D. Effect of fish oil on circulating adiponectin: a systematic review and meta-analysis of randomized controlled trials.doi:10.1210/jc.2012-3899 · PMID 23703724
14 placebo-controlled trials (682 vs 641): +0.37 micrograms/mL (0.07-0.67), I2 72.9%, funnel asymmetry; trim-and-fill 0.18 (-0.15 to 0.52); fish meals no effect.
- 121Musazadeh V, Abbasi S, Kavyani Z, et al. The effect of curcumin supplementation on circulating adiponectin and leptin concentration in adults: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials.doi:10.1017/S0007114523002428 · PMID 37980942
13 RCTs (14 arms): adiponectin SMD 0.86 (0.33-1.39) with I2 93.1%. Published online November 2023.
- 122Abbasi S, Karimi K, Hossein Moridpour A, Musazadeh V, Faghfouri AH, Jozi H. Can flaxseed supplementation affect circulating adipokines in adults? An updated systematic review and meta-analysis of randomized controlled trials.doi:10.3389/fnut.2023.1179089 · PMID 37743909
13 RCTs: no significant effect on adiponectin, SMD 0.52 (-0.20 to 1.25), I2 92%.
- 123Naseri K, Saadati S, Ghaemi F, et al. The effects of probiotic and synbiotic supplementation on inflammation, oxidative stress, and circulating adiponectin and leptin concentration in subjects with prediabetes and type 2 diabetes mellitus: a GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials.doi:10.1007/s00394-022-03012-9 · PMID 36239789
32 RCTs in prediabetes and type 2 diabetes: no significant change in adipokines including adiponectin.
- 124Karimi M, Alipour S, Pirzad S, Ahmadizad S, Bassami M, Asbaghi O. Effect of Vitamin E on Serum Adiponectin and Leptin in Adults: A Systematic Review and Meta-analysis.doi:10.1080/19390211.2025.2561143 · PMID 41063466
10 RCTs: no significant overall change in adiponectin; positive only in subgroups (over 12 weeks, fatty liver). Units printed as ng/mL.
- 125Sharifi S, Talebi S, Nattagh-Eshtivani E, Amiri Y, Askari G. The Effect of Garlic (Allium sativum L) Supplementation on Circulating Adiponectin: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.doi:10.7762/cnr.2021.10.3.257 · PMID 34386444
6 trials, 266 subjects: non-significant increase (Hedges g 0.27, -0.07 to 0.62); the authors nonetheless concluded garlic boosts adiponectin in general, a conclusion their data do not support.
- 126Stein E, Garbelotto C, Marcadenti A, et al. Comparable effects of low-carbohydrate and low-fat diets on inflammatory markers and adipokines: A systematic review and meta-analysis of randomized trials.doi:10.1016/j.nutres.2026.03.010 · PMID 42127582
25 RCTs, 2,222 adults, median 24 weeks: no significant difference between low-carbohydrate and low-fat diets for adiponectin, leptin, resistin or inflammatory markers.
- 127Turner L, Charrouf R, Martínez-Vizcaíno V, Hutchison A, Heilbronn LK, Fernández-Rodríguez R. The effects of time-restricted eating versus habitual diet on inflammatory cytokines and adipokines in the general adult population: a systematic review with meta-analysis.doi:10.1016/j.ajcnut.2023.10.009 · PMID 37865184
25 studies (13 RCTs, 12 non-RCTs), 936 participants: adiponectin SMD 0.07 (-0.40 to 0.54) across 6 comparisons. Published online 20 October 2023.
- 128Tavakoli A, Bideshki MV, Zamani P, et al. The effectiveness of fasting regimens on serum levels of some major weight regulating hormones: a GRADE-assessed systematic review and meta-analysis in randomized controlled trial.doi:10.1186/s41043-025-00834-1 · PMID 40176106
16 reports of RCTs of intermittent fasting, time-restricted feeding, alternate-day fasting and fasting-mimicking diets: adiponectin WMD 0.41 micrograms/mL (-0.07 to 0.89), p = 0.09, described by the authors as marginally significant.
- 129Xiao GL, Wang T, Kuang J, et al. The effect of ketogenic diet on adipokines levels: a systematic review and meta-analysis of randomized-controlled trials.doi:10.1007/s00592-024-02362-6 · PMID 39302468
22 studies: leptin lower on a ketogenic diet; no discernible effect on adiponectin or ghrelin.
- 130Sánchez-Rosales AI, Guadarrama-López AL, Gaona-Valle LS, Martínez-Carrillo BE, Valdés-Ramos R. The Effect of Dietary Patterns on Inflammatory Biomarkers in Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.doi:10.3390/nu14214577 · PMID 36364839
10 RCTs in type 2 diabetes: Mediterranean, Diabetes Prevention Program and Diabetes UK patterns raised adiponectin, SMD 0.81 (99% CI 0.06-1.56), I2 96%; low-to-moderate quality evidence.
- 131Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies.doi:10.1136/bmj.d636 · PMID 21343206
63 interventional studies (44 meta-analyzed) in adults without known cardiovascular disease: adiponectin +0.56 mg/L (0.39-0.72); HDL up, fibrinogen down. The authors read these as indirect support for a protective effect of moderate drinking.
- 132Lin J, Lei L, Liang Q, et al. Assessment of causality association between serum adiponectin levels and the risk of Alzheimer's disease and Parkinson's disease: a Mendelian randomization study.doi:10.3389/fneur.2025.1395798 · PMID 40371086
Two-sample bidirectional MR with IEU GWAS data: Alzheimer's disease OR 0.852 (0.586-1.117, interval as printed), Parkinson's 0.830; no causal association in either direction.
- 133Sun W, Luan H, Li S, et al. Circulating adipokines level and the risk of neurodegenerative diseases: a two-sample mendelian randomization study and proteomic analysis.doi:10.1186/s12883-026-04636-8 · PMID 41545942
Adiponectin GWAS of 39,883 people as exposure: Alzheimer's disease OR 0.79 (0.65-0.96); no effect of leptin, resistin or MCP-1 on Alzheimer's, Parkinson's or ALS.
This is education, not medical advice. Nothing on this page is written with knowledge of your history, your medications or your risks, and nothing here is a dose. Do not start or stop any treatment on the basis of it — talk to your own physician. Read the full medical disclaimer.

